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Abstract 
Alzheimer’s disease (AD) is a complex neurodegenerative disease affecting the 
cholinergic region of the brain. Its prevalence is steadily increasing and it is becoming one of the 
highest costing diseases to modern society. Current drug therapies only provide symptomatic 
relief and are not a viable option for long-term treatment. Thus, there is a need for more effective 
disease-modifying therapeutics. Since the discovery of AD, research in the field has led to a 
number of proposed theories behind the causes of AD including the (i) cholinergic hypothesis (ii) 
amyloid beta hypothesis and (iii) oxidative stress hypothesis. The major class of drug therapies 
are cholinesterase inhibitors; however, this “one drug, one target” approach has proved to be 
ineffective during the later stages of disease progression. Here we examined two novel classes of 
tricyclics; phenothiazines (5, 6, 7a-l) and phenoselenazines (13, 14, 15a-l) to target the 
cholinesterases (ChE), amyloid aggregation, and oxidative stress pathways of AD. This new 
design approach is aimed at discovering potential disease-modifying therapeutics with multi-
targeting abilities. Chapter 1 encompasses background information pertaining to the role of each 
hypothesis in AD including the cholinesterase, amyloid and oxidative stress hypothesis. Chapter 
2 provides a summary of the design and hypothesis behind the project. Chapter 3 describes the 
chemistry conducted including the chemical protocols, reaction schemes and mechanisms in 
synthesizing the target molecules. Chapter 4 reviews the biological evaluation and the SAR 
analysis of the synthesized compounds. Furthermore, it describes the principles behind the 
biological assays conducted including cholinesterase inhibition, amyloid aggregation inhibition, 
antioxidant properties and cell viability in neuroblastoma cell lines. Chapter 5 consists of the 
molecular modeling results and their application to help rationalize the results in both the 
cholinesterase and amyloid aggregation SAR data. Chapter 6 reviews all the data acquired and 
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provides ideas for future directions. Finally chapter 7 provides the full experimental details for 
synthetic chemistry as well as the analytical data for synthesized compounds and protocols for 
biological evaluations. The research project conducted identified novel tricyclics as dual 
cholinesterase inhibitors with multi-target abilities in anti-amyloid aggregation inhibition and 
antioxidant properties. The most potent AChE inhibitor was 15d ((4-methoxyphenyl)-10H-
phenoselenazin-10-ylmethanone; AChE IC50 = 4.63 µM), whereas the most potent BuChE 
inhibitor was 13 (10H-phenoselenazine; BuChE IC50 = 3.00 µM). Overall the best dual 
cholinesterase derivative was identified as compound 15j (2-chloro-10H-phenoselenazin-10-
yl(4-methoxyphenyl)methanone; AChE IC50 = 5.79 µM, BuChE IC50 = 4.91 µM). Both PTZ and 
PSZ derivatives exhibited good antioxidant properties with weak anti-aggregation activity. In 
conclusion, our studies provide a new class of tricyclics in the design and development of small 
molecules to target multiple pathways of AD.  
 
 
 
 
 
 
 
 
 
v 
 
Publications 
1. Tarek Mohammed, Wesseem Osman, Gary Tin, Praveen P.N. Rao. Selective inhibition of 
human acetylcholinesterase by xanthine derivatives: In vitro inhibition and molecular modeling 
investigations. Bioorg. Med. Chem. Lett. 23, 4336-4341 (2013). 
 
Conference Presentations: 
2. Gary Tin, Tarek Mohamed, Praveen Nekkar Rao, Design, Synthesis and Biological 
Evaluation of Novel Phenothiazines: Dual Cholinesterase (ChE), Amyloid Aggregation 
Inhibitors with Antioxidant Properties. Canadian Society for Chemistry: Canadian Chemistry 
Conference and Exhibition (2014). 
 
 
 
 
 
 
 
 
 
vi 
 
Acknowledgements 
 I would like to extend my thanks to the University of Waterloo’s School of Pharmacy for 
supporting the presented work and also to the graduate studies office for their funding of the 
project and conference expenses. 
 I also want to thank MITAC’s Canada and Cyclica Inc. for allowing me the opportunity 
to participate in their internship program, which helped me gain exposure to the industry and add 
to my overall graduate experience. 
 I would also like to acknowledge Tarek Mohammed and Wessem Osman for their 
expertise during the project as mentors. I would like to extend my thanks to Nyasha Gondora and 
Dr. Michael Beazely for providing MTT cell viability assay data. Finally, I would like to 
acknowledge Katherine Tran for her dedication and hardwork with the project during her time as 
a lab volunteer in our research group. 
 
 
 
 
 
 
 
vii 
 
Dedication 
 I would like to dedicate the efforts presented here to my parents, Amos Tin and Quinnie 
Mok, my aunt, Emily Tin, and my grandma, Wong Wei Ching who have given me their full 
support throughout my graduate career. I would also like to thanks all my friends and colleagues 
who helped me on my journey, especially Natalie Wong for her unwavering support. Lastly, I 
would like to dedicate my work to Dr. Praveen Nekkar for not only giving me this great 
opportunity, but for helping me obtain work experience through a MITACs internship, and also 
for supporting me throughout my masters project. Finally, I would also like to extend my 
appreciation to my committee members, Dr. Michael Beazely and Dr. Gary Dmitrienko for their 
advice and support over the last 2 years. 
 
 
 
 
 
 
 
 
 
viii 
 
Table of contents 
Abstract           iii 
Publications           v 
Acknowledgements          vi 
Dedications           vii 
List of Figures           xiii 
List of Tables           xviii 
List of Schemes          xix 
List of Abbreviations          xx 
Chapter 1: Introduction         1 
1.1 Background of Alzheimer’s Disease      1 
1.2 Cholinergic Hypothesis        4 
1.3 Amyloid Hypothesis        8 
1.3.1 Anti-amyloid strategies      10 
1.4 Oxidative Stress Hypothesis       14 
1.5 Conclusion         19 
Chapter 2: Hypothesis and Design Rationale      21 
2.1 Proposal          21 
2.2 Phenothiazines         22 
2.3 Phenoselenazines         22 
ix 
 
2.3.1 Selenium        23 
2.4 Conclusion         24 
Chapter 3: Chemistry         25 
3.1 Introduction         25 
3.2 Proposal          25 
3.2.1 Synthesis of PTZ Derivatives      25 
3.2.2 Synthesis of PSZ Derivatives      26 
3.3 Results          26 
3.3.1 PTZ Derivatives       26 
3.3.2 PSZ Derivatives       27 
3.3.2.1 Diphenylamine synthesis     27 
3.3.2.2 Phenoselenazine synthesis     29 
3.3.2.3 N10 Derivative synthesis     30 
3.4 Mechanisms and Protocols       30 
3.4.1 PTZ Derivatives       30 
3.4.2 PSZ Derivatives       31 
3.4.2.1 Diphenylamine (DPA) synthesis    31 
3.4.2.2 Phenoselenazine (PSZ) synthesis    36  
3.4.2.3 Synthesis of N-acyl-PSZ derivatives    39 
3.5 Conclusion         39 
Chapter 4: Biological Evaluation        40 
4.1 Introduction         40 
4.2 Human Cholinesterase Inhibition Studies     40 
x 
 
4.2.1 Assay Principle       40 
4.3 Results and Discussion        41 
4.3.1 PTZ Derivatives SAR       41 
4.3.2 PSZ Derivatives SAR       45 
4.4 Conclusion         49 
4.5 Amyloid Aggregation Inhibition Studies      51 
4.5.1 Assay Principle       51 
4.6 Results and Discussion        52 
4.6.1 PTZ Derivatives SAR       52 
4.6.2 PSZ Derivatives SAR       54 
4.7 Conclusion         56 
4.8 Antioxidant Assay        57 
4.8.1 Assay principle       57 
4.9 Results and Discussion        58 
4.9.1 PTZ Derivatives SAR       58 
4.9.2 PSZ Derivatives SAR       59 
4.10 Conclusion         61 
4.11 Evaluation of Cell Viability       62 
4.11.1 Assay Principle       62 
4.12 Results and Discussion       63 
4.12.1 PTZ Derivatives SAR       63 
4.12.2 PSZ Derivatives SAR       64 
4.13 Conclusion         66 
xi 
 
Chapter 5: Molecular Docking Studies       67 
5.1 Introduction         67 
5.2 Principle          67 
5.3 Results and Discussion        69 
5.3.1 Molecular docking of PTZ derivatives with ChE’s   69 
5.3.2 Molecular docking of PSZ derivatives with ChE’s    73 
5.3.3 ChE Comparisons       76 
5.3.4 Molecular docking of PTZ derivatives with amyloid dimer  79 
5.3.5 Molecular docking of PSZ derivatives with amyloid dimer  80 
5.3.6 Amyloid Comparisons      82 
5.4 Conclusions         83 
Chapter 6: Conclusion and Future Directions      84 
6.1 Conclusion         84 
6.2 Future Directions         86 
Chapter 7: Experimental         88 
7.1 Chemistry          88 
7.1.1 General method for the preparation of PTZ derivatives (7a-l) 89 
7.1.2 General method for the preparation of diphenylamines  91 
7.1.3 General method for the preparation of PSZ’s (13 and 14)  94 
7.1.4 General method for the preparation of PSZ derivatives (15a-l) 95 
7.2 Biochemistry         98 
7.2.1 Cholinesterase Assay       98 
7.2.2 Anti-Amyloid aggregation Assay     99 
xii 
 
7.2.3 DPPH Antioxidant Assay      101 
7.2.4 MTT Cell Viability Assay      101 
7.3 Computational Chemistry        102 
7.4 Appendix A: UV scan of compounds 13 and 15f at 50 µM in methanol  103 
References          104 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
xiii 
 
List of Figures 
Chapter 1 
Figure 1.1: Mechanism of AChE hydrolysis by cholinesterases    5 
Figure 1.2: Active site details of mammalian AChE (A) and BuChE (B)   7 
Figure 1.3: Chemical structures of currently marketed cholinesterase inhibitors  8  
Figure 1.4: The amyloid cascade (amyloidogenic and non-amyloidogenic pathways) 10 
Figure 1.5: Chemical structures of semgacestat, tarenflubril and tramiprostate  14 
Figure 1.6: Chemical structures of vitamin E, curcumin and clioquinol   15 
Figure 1.7: Summary of oxidative stress in AD pathophysiology    17 
Figure 1.8: Chemical structures of Rember and memantine     20 
Chapter 2 
Figure 2.1: Chemical structure of tacrine       21 
Figure 2.2: Proposed phenothiazines and phenoselenazines     21 
Figure 2.3: Chemical structures of chlorpromazine (1) and fluphenazine (2)  22 
Figure 2.4: Chemical structures of some bioactive phenoselenazines (3) and (4)  23 
Figure 2.5: Examples of selenium-containing biomolecules and compounds  24 
Chapter 3 
Figure 3.1: PTZ compound library synthesized      25 
Figure 3.2: PSZ compound library synthesized      26 
Figure 3.3: General setup for the synthesis of PTZ derivatives 7a-l    31 
Figure 3.4: A proposed mechanism of action for Scheme 2     32 
Figure 3.5: A proposed general mechanism of the copper-catalyzed DPA synthesis (Chan-Lam 
coupling)           33  
xiv 
 
Figure 3.6: Proposed mechanism of action for Scheme 3.5, synthesis of α-iodinated 2-cyclohex-
2-enone  (10)           34 
Figure 3.7: Proposed mechanism of action for Scheme 3.6, the second step of the metal-free 
approach           35 
Figure 3.8: General setup for the synthesis of DPA (11) or 3-chloro DPA (12)  36 
Figure 3.9: In-situ regeneration of selenium for Scheme 3.8   37 
Figure 3.10: Proposed mechanism for the synthesis of phenoselenazine (13) and 2-
chlorophenoselenazine (14)         38 
Figure 3.11: General setup for synthesis of phenoselenazine (13) and 2-chlorophenoselenazine 
(14)            38 
Figure 3.12: General setup for the synthesis of PSZ derivatives 15a-l   39 
Chapter 4 
Figure 4.1: Cholinesterase assay principle       41  
Figure 4.2: Graphical summary of chlorine’s effect on BuChE inhibition of PTZ series. Results 
are expressed as average ± SD (n = 3) of two independent experiments Error bars represent 
standard deviation          43 
Figure 4.3: Graphical summary of chlorine’s effect on BuChE inhibition of PSZ series. Results 
are expressed as average ± SD (n = 3) of two independent experiments. Error bars represent 
standard deviation          47 
Figure 4.4: Top candidates from the PTZ series from cholinesterase inhibition  50 
Figure 4.5: Top candidates from the PSZ series from cholinesterase inhibition  50 
Figure 4.6: Anti-amyloid aggregation assay principle     51 
xv 
 
Figure 4.7: Aβ1-42 aggregation kinetic data for compounds 5 at 37 
◦
C, 16 hr incubation in sodium 
phosphate buffer at pH 8.5         54 
Figure 4.8: Aβ1-42 aggregation kinetic data for compounds 13 and at 37 
◦
C, 16 hr incubation 
sodium phosphate buffer at pH 8.5        56 
Figure 4.9: Chemical structures of top compounds with anti-Aβ1-42 aggregation activity 57 
Figure 4.10: DPPH radical scavenging assay principle     57 
Figure 4.11: Mechanism of PTZ and PSZ based antioxidants    62 
Figure 4.12: Chemical structures of top PTZ and PSZs with antioxidant properties  62 
Figure 4.13: MTT based cell viability assay principle     63 
Figure 4.14: Chemical structures of top PTZ and PSZ with good cell viability  66 
Chapter 5 
Figure 5.1: Schematics of molecular docking in conjunction with experimental methods 68 
Figure 5.2: Docking of 10-H-phenothiazine (5) in the active site of hAChE (A) and hBuChE (B). 
Hydrogen atoms are not shown for clarity. Red: catalytic triad, Green: cationic site, Blue: PAS 
            69 
Figure 5.3: Docking of 1-(2-chloro-10H-phenothiazin-10-yl)-2-phenylethanone (7h) in the active 
site of hAChE (A) and hBuChE (B). Hydrogen atoms are not shown for clarity. Red: catalytic 
triad, Green: cationic site, Blue: PAS        70 
Figure 5.4: Docking of 2-chloro-10H-phenothiazin-10-yl (4-methoxyphenyl)methanone (7j) in 
the active site of hAChE (A) and hBuChE (B). Hydrogen atoms are not shown for clarity. Red: 
catalytic triad, Green: cationic site, Blue: PAS      71 
xvi 
 
Figure 5.5: Docking of 10-H-phenoselenazine (13) in the active site of hAChE (A) and hBuChE 
(B). Hydrogen atoms are not shown for clarity. Red: catalytic triad, Green: cationic site, Blue: 
PAS            73 
Figure 5.6: Docking of 2-chloro-10H-phenoselenazin-10-yl (phenyl) methanone (15g) in the 
active site of hAChE (A) and hBuChE (B). Hydrogen atoms are not shown for clarity. Red: 
catalytic triad, Green: cationic site, Blue: PAS      74 
Figure 5.7: Docking of 2-chloro-10H-phenoselenazin-10-yl (4-methoxyphenyl)methanone (15j) 
in the active site of hAChE (A) and hBuChE (B). Hydrogen atoms are not shown for clarity. Red: 
catalytic triad, Green: cationic site, Blue: PAS      75 
Figure 5.8: Comparison of binding modes 10-H-phenothiazine (5, yellow) and 10-H-
phenoselenazine (13, purple) in the active site of hAChE (A) and hBuChE (B). Hydrogen atoms 
are not shown for clarity. Red: catalytic triad, Green: cationic site, Blue: PAS  76 
Figure 5.9: Comparison of binding modes of 2-chloro-10H-phenothiazin-10-yl (4-
methoxyphenyl)methanone (7j, yellow) and 2-chloro-10H-phenoselenazin-10-yl (4-
methoxyphenyl)methanone (15j, purple)  in the active site of hAChE (A) and hBuChE (B). 
Hydrogen atoms are not shown for clarity. Red: catalytic triad, Green: cationic site, Blue: PAS 
            77 
Figure 5.10: Comparison of binding modes of 10H-phenoselenazin-10-yl (phenyl)methanone 
(15a, purple) and 2-chloro-10H-phenoselenazin-10-yl (phenyl)methanone (15g) in the active site 
of hAChE (A) and hBuChE (B). Hydrogen atoms are not shown for clarity. Red: catalytic triad, 
Green: cationic site, Blue: PAS        78 
xvii 
 
Figure 5.11: Docking of 10-H-phenothiazine (5, A) and 2-chloro-10-H-phenothiazine (6, B) in 
the amyloid beta dimer model. Hydrogen atoms are not shown for clarity. Red: Chain A, Blue: 
Chain B           79 
Figure 5.12: Docking of 10-H-phenoselenazine (13, A) and 2-chloro-10-H-phenoselenazine (14, 
B) in the amyloid beta dimer model. Hydrogen atoms are not shown for clarity. Red: Chain A, 
Blue: Chain B           80 
Figure 5.13: Comparison of binding modes of 10-H-phenothiazine (5, yellow) and 10-H-
phenoselenazine (13, purple) in the Aβ dimer model. Hydrogen atoms are not shown for clarity. 
Red: Chain A, Blue: Chain B         82 
Chapter 6 
Figure 6.1: Future development of novel PTZ and PSZ derivatives    87 
Chapter 7 -  Appendix A 
Figure A.1: UV scan of compound 13 at 50 µM in methanol    103 
Figure A.2: UV scan of compound 15f at 50 µM in methanol    103 
 
 
 
 
 
 
 
 
xviii 
 
List of Tables 
Chapter 4 
Table 4.1: Cholinesterase inhibition, Selectivity Index and ClogP values of PTZ series 44 
Table 4.2: Cholinesterase inhibition, Selectivity Index and ClogP values of PSZ series 48 
Table 4.3: Self-induced amyloid (Aβ1-42) inhibition data for PTZ derivatives  53 
Table 4.4: Self-induced amyloid (Aβ1-42) inhibition data for PSZ derivatives  55 
Table 4.5: DPPH radical scavenging by PTZ derivatives     59 
Table 4.6: DPPH radical scavenging by PSZ derivatives     60 
Table 4.7: Percent viability of SH-SY5Y cell line after treatment with PTZs  64 
Table 4.8:  Percent viability of SH-SY5Y cell line after treatment with PSZs  65 
 
 
 
 
 
 
 
 
 
xix 
 
List of schemes 
Chapter 3 
Scheme 3.1: Synthesis of PTZ derivatives 7a-l      27 
Scheme 3.2: Copper-mediated synthesis of DPA (11), 3-Cl DPA (12) – method 1  27 
Scheme 3.3: Copper-mediated synthesis of DPA (11), 3-Cl DPA (12) – method 2  28 
Scheme 3.4: Copper-mediated synthesis of DPA (11), 3-Cl DPA (12) – method 3  28 
Scheme 3.5: Metal-free synthesis of DPA (11), 3-Cl DPA (12) – step 1, formation of an α-
iodinated cyclohex-2-ene (10)        28 
Scheme 3.6: Metal-free synthesis of DPA (10), 3-Cl DPA (12) – step 2   28 
Scheme 3.7: Phenoselenazine (13, 14) synthesis (method 1)     29
 
Scheme 3.8: Phenoselenazine (13, 14) synthesis (method 2)     29 
Scheme 3.9: Synthesis of PSZ derivatives 15a-l      30 
 
 
 
 
 
 
 
 
 
xx 
 
List of abbreviations 
Aβ – Beta amyloid 
ACh – Acetylcholine 
AChE –Acetylcholinesterase 
AChEIs – Acetylcholinesterase inhibitors 
AD - Alzheimer’s disease 
APP – Amyloid precursor protein 
Asp – Aspartate 
BuChE – Butyrylcholinesterase 
ChAT – Cholineacetyltransferase 
ChE - Cholinesterase 
CNS - Central nervous system 
DCM – Dichloromethane  
DPA – Diphenylamine 
DPPH - 2,2-Diphenyl-1-picrylhydrazyl 
EtOAc – Ethylacetate 
FDA – Food and Drug Administration 
Glu - Glutamate 
His – Histidine 
HPLC – High performance liquid chromatography 
MgSO4 – Magnesium sulfate 
mL – Millilitre 
mmol – Millimole  
xxi 
 
MP – Melting point 
MS – Mass spectrometry 
NFT - Neurofibrillary tangles 
NMR – Nuclear magnetic resonance 
PAS - Peripheral anionic site 
PSZ – Phenoselenazine 
PTZ – Phenothiazine 
PUFA – Poly unsaturated fatty acid 
RBF – Round bottom flask 
RM – Reaction mixture 
ROS – Reactive oxygen species  
SAR – structure activity relationship 
Ser – Serine 
SD – Standard deviation 
ThT – Thioflavin T 
TLC – Thin layer chromatography 
Trp – Tryptophan 
Tyr – Tyrosine 
UPW – Ultra pure water  
 1 
 
Chapter 1: Introduction 
1.1 Background on Alzheimer’s Disease 
Alzheimer’s disease (AD) is a complex neurodegenerative disorder that affects areas of the brain 
dealing with memory, cognition and function. Over 30 million people worldwide suffer from AD, 
and that number is expected to increase significantly in the near future.
1
 The current drug 
therapies on the market are palliative and without further intervention, the widespread burden of 
the disease will only increase with time.
2
 There is not yet a cure for AD, thus there remains a 
necessity to develop drugs that contain disease-modifying properties that may alter the course 
and slow disease progression. 
AD is the most common type of dementia
3
; where dementia is classified as any individual who 
suffers from either mild or major neurocognitive dysfunction that affects their ability to perform 
tasks in daily life settings. Dementia is the outcome of damaged neurons, which leads to 
impaired cognitive function. There are many types of dementia, each with their own unique 
characteristics and disease hallmarks. In the case of AD, which accounts for over 60% dementia 
cases, one of the earliest symptoms is the decline in one’s memory. Hallmarks of the disease 
include pathological extracellular plaques and neurofibrillary tangles.
4
 More pronounced 
symptoms that appear later on in the disease include: confusion, sporadic behavior, aggression, 
disorientation etc. In severe cases the sufferer is unable to perform daily tasks by themselves 
such as walking, speaking and swallowing, and requires full commitment from caregivers to 
attend to them. Altogether AD ultimately leads to death.
1 
The prevalence of those inflicted with AD is becoming a staggering problem in developed 
societies. While most of the other major diseases have seen marked decrease in numbers, AD is 
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the only major disease that has been on the rise. In 2010 there was an estimated 36 million 
people with dementia and the number is expected to double every 20 years, which is a concern 
worldwide.
5 
The biggest concern that AD places, besides the disease itself inflicted on the primary patient, is 
the secondary and tertiary effects it has on caregivers and the economy respectively. On average 
individuals diagnosed with AD have a life expectancy of around 6 years after the onset of 
various clinical symptoms.
2
 This number will vary based on a number of factors including age, 
genetics, quality and access to care, etc. AD is especially devastating due to its prolonged length 
of progression; whereby primary caregivers – most usually family members – are placed with the 
task of attending to the needs of the patient.
1
 Home care is generally preferred as the healthcare 
costs of hospitalized institutions are enormous. There have been multiple studies on the social 
and psychological burdens that AD places on caregivers, adding to the overall implications of the 
disease. Due to the erratic behavioural changes implicated by a typical AD patient, the amount of 
stress placed on the primary caregiver is immense, especially during the later stages of the 
disease when symptoms are most severe. Primary caregivers are placed at high risk of 
developing a multitude of physical and mental disorders from the demanding work of dealing 
with AD patients.
5 
The other complex aspect of AD is the immense cost – both direct and indirect – it places on the 
economy. While AD may not be prevalent in third world countries, it ranks among the highest 
costing diseases in developed societies.
5
 In terms of direct cost, an estimated 150 billion dollars 
will be spent in 2014 in the US on medicare towards AD health care, long-term care and 
hospice.
1
 With the disease prevalence rising at an alarming rate, the impact and burden on the 
economy will be unbearable. The long-term hospital care required to house patients remains one 
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of the biggest issues moving forward for health care. Aside from hospital care, there is also the 
cost associated with specialized in-home social workers, since in the case of AD, round-the-
clock supervision is vital for high quality care. The indirect costs of AD also accumulate from 
both the lost productivity of the patient and the caregiver. Especially in the case of in-home care, 
primary caregivers in the US alone provided an estimated 17.7 billion informal care (unpaid 
hours) in 2013.
5
 These figures, classified as “unpaid caregivers”, make up the bulk of the indirect 
costs lost due to AD. 
Various risk factors play important roles in AD pathophysiology. The biggest risk factor is age. 
Approximately 95% of the patients living with AD are 65 or older, while the other 5% diagnosed 
with early on-set AD, is due to genetics.
1
 About one third of the population aged 85 or older have 
AD, showing that age is a major driver in AD development. Another important risk factor is the 
genetic risk which can promote the early on-set familial AD (FAD). Mutations in specific genes 
cause the early on-set and progression in individuals compared to the regular sporadic AD 
(SAD).
6
 Although FAD only accounts for approximately 1% of all AD cases, the findings from 
the studies have generated a breadth of knowledge that has been crucial in our understanding of 
the disease.
7
 Autosomal dominant mutations in the genes encoding for either APP, presenilin 1 
(PSEN1) or PSEN2 cause the FAD by increasing the mis-processing of APP. The major genetic 
risk factor is the apolioprotein E (APOE).
8
 Humans contain three alleles of APOE; APOE2, 
APOE3 and APOE4. Carrying the APOE4 could potentially initiate disease progression at a 
much earlier age than SAD does. The APOE proteins play a role in AD in mediating the 
clearance of beta amyloid. The protein APOE2 is considered to be neuroprotective, where as 
APOE3 is considered to be neutral, and APOE4 is considered to be a risk factor as it is least 
efficient at clearing Aβ. While a large percentage of the population carries the APOE3 allele, the 
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25% of the population that carries the APOE4 allele bear a much higher risk of developing AD. 
Approximately 60% of all AD patients carry at least one copy of the APOE4 gene.
1 
With the increasing global population, lifespan and baby-boomers, AD will be of great concern 
in the very near future. The societal and economic cost of AD will be prohibitively expensive. 
These factors support the development of novel disease modifying therapeutics to slow or even 
halt disease progression. 
1.2 Cholinergic Hypothesis 
The first and oldest hypothesis of AD, states that AD originates due to a deficiency of the 
cholinergic neurons. The main neurotransmitter implicated in AD disease pathology, 
acetylcholine (ACh), has been studied extensively for its role in cognitive function.
9
 It is known 
to play an important role in the brain dealing with memory, learning and cognition. The 
therapeutic rationale behind developing drugs that tackle this issue arose after the discovery of 
altered ACh levels in AD brains. Results from these studies showed a marked decrease in the 
synthesis of ACh located in the pre-synaptic region of the brain, nucleus basalis of Meynert.
10
 
These findings led to the view that the deterioration of memory and cognition is caused by this 
deficiency of ACh available for cholinergic transmission.
11
 The proposed pharmacological 
mechanism became the subject of focus, dedicating research into the discovery of 
acetylcholinesterase inhibitors (AChEIs) as one possible form of treatment.
12
 This is the most 
widely accepted hypotheses relating to AD and remains the main target for current AD therapies. 
The cholinesterase (ChE) enzymes, acetylcholinesterase (AChE) and butyrylcholinesterase 
(BuChE) belong to a family of α/β hydrolases that mediate the breakdown of ACh. Both 
enzymes share a 60% sequence homology, but AChE is the primary enzyme implicated in AD 
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since it is located in neural synapses.
13
 Its primary role in normal physiology is to terminate 
synaptic transmission of ACh, breaking it down into acetate and choline. (Figure 1.1) Both 
enzymes’ active site contains the typical catalytic triad consisting of serine, histidine and 
glutamate (instead of aspartate).
14
 A general mechanism of the acetylcholine catalysis is shown 
below. 
 
 
 
 
 
 
 
 
Figure 1.1: Mechanism of AChE hydrolysis by cholinesterases 
AChE is recognized as the primary enzyme responsible for the breakdown of ACh. It is located 
throughout the body at neuromuscular junctions and also in the cholinergic brain synapses. The 
AChE of interest pertaining to AD is the membrane-bound version found in the CNS that 
mediate the termination of neural transmission.
15
 Its crystal structure has been studied 
extensively and it is unique in that the active site is located deep within the enzyme in a 20 Å 
gorge.
16
 Numerous residues at the opening of the active site resemble a bottleneck-like shape 
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guiding its natural substrate, ACh downwards. Precise components of the enzyme help increase 
its specificity, including the key stabilizing Trp86 residue of the hydrophobic pocket; Phe295 
and Phe297, forming the acyl pocket that stabilizes the acetyl end of ACh. (Figure 1.2) Another 
interesting region in AChE besides the active site is the peripheral anionic site (PAS) located at 
the opening comprised of Trp286.
17
 Not only does this anionic site serve to help guide substrates 
into the active site, it has been implicated that it plays a key role in the AChE-mediated Aβ 
aggregation. The presence of various hydrophobic residues acts as a seeding point for Aβ 
peptides to amass, causing the formation of a highly toxic AChE-Aβ complex that promotes 
further aggregation of neurotoxic aggregates.
18 
 
While AChE is the primary enzyme, BuChE is recognized as the “secondary” cholinesterase in 
the body. 
19 
Produced by the liver, this enzyme is mainly present in the plasma. Its main 
biological function was thought to serve as a backup towards AChE, until it was found to help 
hydrolyze a number of different substrates including the recreational alkaloid, cocaine.
20
 Its 
clinical significance is now recognized as a potential safeguard to neurotoxic anti-cholinesterase 
agents by helping the breakdown of these compounds before they are able to reach neuronal 
junctions.
21
 Structurally, BuChE is similar to AChE in that it still has its active site gorge 20 Å 
deep within the enzyme. The catalytic triad also remains similar with the serine, hisitine and 
glutamate. The same Trp82 is present as the key stabilizing residue for catalytic activity. (Figure 
1.2) Major structural differences include the replacement of many of the aromatic residues at the 
opening with smaller residues, making the entrance to the active site much less restrictive. The 
acyl pocket is also replaced with smaller residues of Leu286 and Val288 instead of two Phe’s, 
allowing for a lower overall specificity of substrates. Since the opening and active site is 
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replaced with smaller residues, this results in a much larger active site volume, approximately 
200 Å
3
 larger than AChE.
22 
 
Figure 1.2: Active site details of mammalian AChE (A) and BuChE (B) 
The AChEIs were introduced as pharmacotherapy option in AD, as they were able to prevent the 
hydrolysis of ACh and promote cholingeric transmission to enhance cognition.
23
 Current drug 
therapies with AChEIs offer limited benefit since they do not modify the disease progression, but 
rather, only slow the onset of symptoms by modulating cholinergic transmission. In advanced 
stages of AD, when the neurons succumb to the various toxic factors and begin to deteriorate, the 
use of AChEIs would no longer be viable.
24
 There have been multiple studies that show 
galantamine’s (Figure 1.3) ability to act as a multi-targeted AChEI.25 While it is a less potent 
AChE inhibitior compared to that of donepezil and rivastigmine (Figure 1.3), its main 
attractiveness as a drug appears to be due to the fact that it also acts as an allosteric modulator of 
Trp286 
Ala277 
His447 
Glu334 
Glu325 
Trp86 
Trp82 
Glu334 
His447 
His438 
A B 
Ser198 
Ser203 
 8 
 
nicotinic acetylcholine receptors (nAChR).
26
 The interaction with nAChRs have been shown to 
help modulate cognitive symptoms and neurodenegerative processes.
27 In addition, AChEI’s 
have been shown to induce the release of other neurotransmitters by acting on the nAChRs. In 
more recent studies, galantamine has also demonstrated to possess the ability to inhibit self-
induced aggregation of Aβ-fibrils and potentially help mediate its cytotoxicity.28 This shows the 
promising potential of a new generation of compounds that inherit a multi-targeted approach by 
possessing disease-modifying capabilities. 
 
Figure 1.3: Chemical structures of currently marketed cholinesterase inhibitors 
1.3 Amyloid Hypothesis 
The amyloid hypothesis arose when deposits of extracellular amyloid senile plaques were 
identified in AD brain samples post-mortem.
29
 It was found that these mis-folded protein 
aggregates were a result of a multitude of cascading events; mis-processing of the amyloid 
precursor protein (APP) through genetic mutations, shift of APP towards the amyloidogenic 
pathway (Figure 1.4), inherent clearance mechanisms of amyloid beta (Aβ) peptides down-
regulated, and elevated levels of aggregates by coordination with various sources.
30
 The presence 
of amyloid plaques in healthy brains, albeit in lower levels, from post-mortem analysis makes it 
unclear whether the on-set of AD is a direct result of the toxic amyloid aggregates.
31
 But studies 
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show that Aβ is implicated as a major hallmark of the disease. Levels of Aβ in AD brains are 
elevated compared to healthy controls supports this arguement.
32
 The Aβ hypothesis was further 
supported by the discovery and elucidation of 3 genetic mutations on APP, PSEN1 or PSEN2 
that cause FAD, and the risk factor of individuals carrying the APOE4 gene.
33
 A number of 
research efforts have been set out to deal with the amyloid hypothesis and various methods have 
been suggested to maintain normal levels of Aβ required for functioning brains. Currently there 
are 3 main views for pharmacotherapy; Blocking the enzymes that processes APP into smaller 
Aβ fragments, blocking the formation and aggregation of Aβ peptides to more toxic oligomeric 
structures, and supplementing clearance mechanisms of the formed Aβ aggregates to reduce the 
amyloid load.
34
 The oligomers formed are the most toxic form of Aβ aggregates. Oligomers are 
found to provide Aβ aggregates as a seeding point, are large enough to be able to disrupt cell 
membranes and neuronal communication through the hindering of synapses, and induce 
intracellular calcium deregulation causing apoptosis through excitoxicity.
35
 There is a 
generalized view that there exists a certain threshold for which Aβ levels must reach in order for 
major disease progression to occur, and once that level is reached, the disease itself becomes Aβ 
independent.
36
 The formed oligomers begin the cascade of forming plaques and re-seeding 
themselves, thus treatment options for the Aβ hypothesis must be introduced before this 
threshold is reached. It is unclear how early on this threshold is implicated and further clinical 
studies needs to be done. In the ideal situation Aβ therapeutics would be given to cohorts of 
individuals with and without AD to examine the complex relationship of the disease process to 
fully elucidate the mechanism of the progression. However, lengthy studies of this magnitude 
require a staggering amount of time and resources. Without enough conclusive evidence the 
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long-term administration of drugs in healthy individuals become substantially difficult due to 
ethical concerns.
37
 
 
 
 
 
 
 
 
 
 
Figure 1.4: The amyloid cascade (amyloidogenic and non-amyloidogenic pathways) 
1.3.1 Anti-amyloid strategies 
Amyloid precursor protein is an integral membrane protein which had an unknown role or 
function up to its discovery. The explosion of interest regarding the amyloid hypothesis has lead 
researchers to delve into this protein to further understand its biological implications. Besides its 
notorious role for being processed into the smaller Aβ fragments, APP’s normal role has been 
found to help with neuronal plasticity and regulate synapse formation.
38
 The issue lies in the 
post-translational processing that APP goes through. There are two pathways; the non-
α-secretase 
β-secretase 
γ-secretase 
Aβ peptide 
(Aβ1-40 and Aβ1-42) 
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amyloidogenic and amyloidogenic (Figure 1.4), regulated by α-secretase and successive actions 
of β and γ-secretases respectively.39 In understanding the dynamic balance between the two APP 
processing pathways, it is established that α-secretase cleaves APP through the non-
amyloidogenic pathway and produces an extracellular fragment that is neuroprotective. 
Researchers have looked at this approach of promoting the balance of APP processing towards 
the non-amyloidogenic pathway as a possible treatment option.
40
 The amyloidogenic pathway 
comprises of successive cleavage of β and γ-secretase. Whereby the initial β-secretase cleavage 
releases an extracellular portion, and a membrane bound fragment called C99. Cleavage of the 
C99 by γ-secretase releases the key Aβ peptide.41 γ-secretase has varied cleavage sites, thus it 
produces Aβ peptide in varied lengths from 39-42 amino acids. The most common form is a 
soluble Aβ1-40 fragment, but it is the insoluble Aβ1-42 form that implicates the most problems in 
AD (Figure 1.4).
42
 The Aβ1-42 form is longer, thus more hydrophobic in nature and is able to 
aggregate quickly via a number of different mechanisms.
43
 The formation of aggregates has been 
studied extensively; starting from the dimerization of two Aβ1-42 peptides, to eventual formation 
of smaller oligomeric peptides (approximately 3 – 10 Aβ1-42 peptides).
44
 Oligomers come 
together in a cross β-sheet conformation generating Aβ-protofilaments, and two protofilaments 
cross together in an intertwining fashion forming the Aβ fibril. Ultimately, when enough of these 
structures come together they form dense insoluble plaques.
45
 A number of different factors 
affect the formation of these plaques in AD-diseased brains. In normal functioning individuals, 
Aβ is processed and inherent clearing mechanisms help reduce the amyloid load. In diseased 
brains, either the clearance mechanisms are hindered or the mis-processing of APP is heightened 
and the buildup of deposited Aβ allows for faster aggregation.46 Once there is an excess of Aβ 
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peptides a number of factors contribute to the aggregation including: i) The biophysical 
properties of Aβ peptides; ii) The PAS of AChE and iii) metal ions mediated aggregation.47, 48, 49 
Aβ peptides have a conserved hydrophobic region that has been identified as the main seeding 
point of self-induced aggregation. The section of residues 15-20 of the Aβ peptide consists of 
KLVFFA.
50
 Drug therapies targeting the self-induced aggregation of single Aβ peptides use this 
section as the starting point for developing aggregation inhibitors. Oligomers are able to form 
highly structured aggregates through cross β-sheet conformations, thus compounds that are able 
to disrupt this specific structure also inhibits aggregation.
51
 Galantamine is an example of such 
inhibitor.
52
 A key link between the cholinergic and amlyoid hypothesis is the AChE-induced 
aggregation of Aβ. The PAS of AChE acts as seeding point of Aβ due to its high concentration 
of aromatic residues.
53
 Metal ions have also been shown to mediate the formation of Aβ 
species.
54
 Three histidine residues, His6, His13 and His14 are conserved across all forms of Aβ 
and act as chelators of metal ions, coordinating around them. Copper, iron and zinc have been 
found to interact with Aβ species generating reactive oxygen species (ROS) that cause oxidative 
damage.
55 
Various phamacotherapies have been researched as possible forms of treatments towards the 
amyloid hypothesis. The idea of inhibiting either β or γ-secretase to limit the formation of Aβ 
species came about as the primary approach to dealing with the amyloid hypothesis. Studies 
done on mice expressing human APP mutations have shown major reduction of Aβ levels that 
lead to improved cognitive function when a β-secretase inhibitor was introduced.56 However, the 
recent failure of β-secretase inhibitors at phase III clinical trials has been a setback to this 
particular route of therapy.
57
 They failed to show any clinical effectiveness over placebo. 
Perhaps further studies involving the concept of the Aβ threshold levels need to be established 
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before re-visiting the use of β-secretase inhibitors.58 γ-secretase also acts as an attractive target, 
and semagacestat (Figure 1.5), a promising drug that reached phase III clinical trials also failed 
to show enough clinical efficacy.
59
 Although work has been done on developing inhibitors, 
human testing has largely remained on hold due to the fact that inhibiting γ-secretase may 
interfere with notch signaling.
60
 In this regard, an alternative method of γ-secretase modulation 
was reviewed. However, the failure of tarenflurbil (Figure 1.5) in phase III clinical trials again 
proved that dealing with the secretases is a complex mechanism that requires further 
investigation.
61
 Aggregation inhibition has been another method used to block the formation of 
Aβ peptides into more toxic oligomers.62 A need for a safer method has been found by either 
inhibiting the self-induced or AChE-induced Aβ aggregates using small molecules. They have 
been developed to be able to coordinate with various Aβ species to prevent the formation of 
higher order toxic oligomers.
63
 Tramiprosate (Figure 1.5) was introduced as an agent to inhibit 
plaque formation by binding to smaller Aβ species, therefore not allowing them to reach higher 
order aggregates. However, its failure to show any clinical significance in phase III stages has 
led researchers into a re-evaluation of Aβ therapeutics.64 The last method found was to aid in the 
reduction of already-formed Aβ plaques.65 In order to help reduce toxicity neuronal damage, 
various methods were applied including the use of Aβ –specific antibodies as a means to 
supplement the body’s clearance mechanisms.66 One such example is bapinezumab, a humanized 
monoclonal antibody using active immunization that recognizes Aβ peptides and helps in the 
clearance mechanisms. Its development was eventually stopped due to a small number of 
patients developing vasogenic edema.
67
 Even though these methods have been reviewed 
extensively, the overall view of the situation on Aβ is nearing a paradigm shift in focusing 
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treatment options mainly on the prevention of Aβ deposition including the clearance of existing 
plaques.
68 
 
Figure 1.5: Chemical structures of semagacestat, tarenflubril and tramiprosate 
1.4 Oxidative Stress Hypothesis 
The oxidative stress hypothesis plays an important part in AD pathogenesis. Oxidative damage is 
regarded as an early event in AD, preceeding the deposition of Aβ and plaques.69 Several studies 
have shown that increasing oxidative stress directly or indirectly increases intracellular Aβ 
levels.
70
 In turn, this increase in levels of Aβ creates a negative feedback cycle that generates 
more reactive oxygen species (ROS). In terms of AD, oxidative stress biomarkers are elevated 
beyond normal levels in the brain indicating that there may be connections with disease 
progression. The AD brain is under significant amounts of oxidative stress in the forms of lipid 
peroxidation, protein oxidation, DNA oxidation, and mitochondrial dysfunction.
71
 Coupled with 
the brain’s natural high requirement for oxygen, high levels of poly unsaturated fatty acids 
(PUFAs) that are easily susceptible to oxidation, and its repressed anti-oxidant defenses it creates 
an environment for oxidative stress to thrive and cause multiple pathways of damage.
72
 A 
number of clinical trials using anti-oxidative agents such as vitamin E and curcumin (Figure 1.6) 
have been underway to test the clinical efficacy of administering anti-oxidants as a potential 
therapeutic treatment.
73
 In vitro experiments involving the use of vitamin E ameliorate oxidative 
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damage, therefore it is believed to be a possible therapeutic option.
74
 Another source to mediate 
oxidative stress is chelation of metal ions. In AD, many metal ions have been shown to take part 
in disease pathology. The Aβ oligomers are notorious for their ability to coordinate with copper 
and iron, and mediating redox reactions generating ROS.
75
 The production of Aβ has also been 
directly involved in promoting a number of oxidative stress pathways including: protein 
oxidation, lipid peroxidation and generation of ROS, indicating key connections between the 
oxidative stress hypothesis and amyloid hypothesis.
76
 Chelation therapy has also been developed 
with drugs like clioquinol (Figure 1.6) and its 2
nd
 generation analog PBT2, for their potential to 
coordinate metal ions to reduce toxicity.
77
 In an attempt to cover multiple targets of disease-
modification, newer drug designs now strive to incorporate anti-oxidant moieties in their design 
in hopes to provide a solution for the oxidative stress hypothesis. 
 
 
 
 
 
Figure 1.6: Chemical structures of vitamin E, curcumin and clioquinol 
Lipid peroxidation in AD is characterized by the degeneration of lipids in cell membranes.
78
 This 
damage is accelerated by the multiple processes that may contribute to the overall cascade; 
decreased biosynthesis, increased degradation and increased lipid peroxidation. One biomarker 
of oxidative stress is the thiobarbituric acid reactive structures (TBARS) as a measure of lipid 
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peroxidation.
79
 In a study with AD and age-matched controls, levels of TBARS in the AD group 
showed evelated levels in the hippocampus.
80
 Lipid PUFAs are abundant in the brain in the 
forms of arachodonic, dosahexenoic, oleic, and stearic acids. A study has shown that all levels of 
these PUFAs are significantly decreased in AD brains versus age-matched controls, matching the 
predicted result that increased levels of lipid peroxidation should decrease the levels of PUFAs.
81
 
Another biomarker is 4-hydroxyalkenals (4-HNE) which is a direct product of PUFA 
peroxidation, specifically, arachadonic and dosahexenoic acids. Levels of 4-HNE are elevated in 
the ventricular cerebrospinal fluid (CSF) of AD patients, which is in direct contact with the brain, 
indicating that it is a potential biomarker for oxidative stress in AD brains.
82
 The 4-HNE is 
responsible for a number of neurotoxic mechanisms; inhibition of DNA, RNA and protein 
synthesis, degradation of enzymes and disrupting calcium homeostasis. Cultured hippocampal 
neurons exposed to Aβ showed significant increase in levels of 4-HNE.78 Another study 
specifically used Aβ1-42 and showed neuronal cultures had increases in levels of 4-HNE, and that 
treatment with vitamin E was an effective treatment in scavenging ROS and stopping the 
oxidative damage.
74
 Additionally, stereotaxic injection of 4-HNE in rat forebrain selectively 
inhibited cholineacetyltransferase (ChAT), that can decrease ACh biosynthesis as indicated in 
the cholinergic hypothesis, which provides another connection between the oxidative stress and 
cholinergic hypothesis.
83
 
Protein oxidation is implicated in age-related neurodegenerative diseases. Vulnerable amino acid 
side chains and the protein backbone are subjects of potential oxidation, and thus the most often 
used biomarker is the protein carbonyl. The oxidative modification of proteins can lead to altered 
functionality, contributing to the overall damage done by oxidative stress.
 84
 In AD, protein 
oxidation has been confirmed. Studies have shown that Aβ1-40, Aβ1-42, Aβ25-35 all directly induce 
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protein oxidation and formation of ROS as levels of protein carbonyls was increased compared 
to controls.
85
 Again, these effects are largely inhibited by the introduction of anti-oxidants. Data 
suggests that in the AD brain protein oxidation is specific towards certain proteins; β-actin and 
creatine kinase BB (CK). This implies that the mechanism of protein oxidation in AD is a 
selective process.
86
 The β-actin is responsible for cell motility and structure and plays an integral 
role in cytoskeletal protein assembly, known to be altered in AD most likely due to ROS-
mediated protein oxidation. The oxidation of CK modifies ATP production in the brain, which is 
required in a number of physiological functions such as controlling ion-pumps, and the synthesis 
of antioxidant proteins. The effects of CK oxidation was inhibited by the introduction of vitamin 
E.
87
 
 
Figure 1.7: Summary of oxidative stress in AD pathophysiology 
As mentioned above in both studies involving lipid and protein oxidation, the damaging effects 
are reduced when an antioxidant such as vitamin E is introduced. The effect of introducing an 
antioxidant is to help stop the further regeneration of ROS to prevent oxidative damage. The 
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added advantage of using vitamins and natural compounds as a source of antioxidants is that they 
are well-characterized and tolerated, thus enrolling the use of vitamin E and C, and curcumin in 
long-term clinical studies has already been underway to validate their therapeutic effects on 
AD.
73, 74
 Introducing compounds that have the potential to coordinate metal ions may be a 
valuable counteractive measure as well. Redox active compounds, copper and iron are known to 
proliferate the generation of ROS in AD.
75
 In addition, Aβ aggregation is known to promote the 
formation of free radicals. Studies have implicated the role of Aβ in causing hydrogen peroxide 
accumulation in cultured hippocampal neurons and its role in inducing lipid peroxidation.
88
 The 
direct influence of Aβ species on the brain’s metal homeostasis has a number of implications. 
Copper, iron and zinc all play a role in mediating Aβ formation through coordination at various 
histidine residues.
76
 The defective regulation of metal homeostasis caused by Aβ leads to 
production of ROS. The study of metal chelators such as PBT2 is one possibility, in hopes to 
provide disease-modifying relief to the oxidative stress hypothesis, it has shown promise in 
phase II clinical trials.
77
 Though further studies are needed to elucidate the complex and multi-
faceted nature of oxidative damage in the AD brain, multiple studies are underway in providing 
antioxidative relief, suggesting that oxidative stress is a viable target to develop anti-AD 
treatments. Figure 1.7 provides a summary of the role of ROS in promoting amyloid toxicity and 
oxidative stress in AD pathophysiology. 
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1.5 Conclusion 
There exist many other potential pathways for therapeutic effects for AD, including tau 
aggregation, modulators, MAO-B inhibitors and NMDA antagonists in an attempt to detect other 
disease-modifying therapeutics. The hyperphosphorylation of tau protein has been overlooked in 
recent years due to pathogenic studies finding that Aβ deposition precedes the downstream 
effects of tau.
89
 Nevertheless, it still remains a prospective target for researchers to pursue. 
LMTX, a prodrug of Rember (Figure 1.8), is a tau aggregation inhibitor that has been enrolled in 
2 phase III clinical trials. From the results shown in phase II, the use of LMTX has looked 
promising.
90 
Tau protein modulators have been pursued as well, where protein kinase inhibitors 
are introduced to potentially block the hyperphosphorylation of tau. The tau protein is involved 
in microtubule stabilization, but hyperphosphorylated tau dissociates from microtubules, thus an 
alternate approach is to design for microtubule-stabilizing remedies.
91
 The MAO-B inhibitors are 
another pathway to help mediate oxidative stress. The MAO-B is an enzyme that catalyzes the 
metabolism of neuroactive amines, and produces ROS in normal physiological conditions.
92
 
Levels of MAO-B are found to be elevated in neurodegenerative diseases such as AD, thus 
introducing inhibitors may help in slowing ROS damage.
93
 Lastly the use of NMDA antagonists, 
namely memantine (Figure 1.8), helps alleviate the excitotoxicity caused by overactivation of 
glutaminegic receptors.
94 
Memantine is the only FDA-approved drug in its class and has been 
found to provide clinically significant improvements when used in conjunction with a 
cholinesterase inhibitor.
95
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Figure 1.8: Chemical structures of Rember and memantine 
Current drug therapies on the market follow the traditional: one drug, one target approach, in the 
form of different drugs targeting different hypotheses of AD. The lack of long-term efficacy of 
these therapeutics has led to a paradigm shift of the outlook towards AD treatment. The focus 
has been shifted to discovering and characterizing potential disease-modifying approaches that 
may slow or even halt the onset of AD. Therefore, there is a mandate for a newer generation of 
compounds with multi-target abilities endowed with these disease-modifying properties that 
tackle multiple pathways of AD as long term treatment options. 
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Chapter 2: Hypothesis and Design Rationale 
2.1 Proposal 
 
Figure 2.1: Chemical structure of tacrine 
The fused tricyclic compound tacrine (Figure 2.1) was the first cholinesterase inhibitor 
developed in the pharmacotherapy of AD. Previous work in Dr. Nekkar Rao’s lab has shown that 
C-9 substituted tacrine derivatives exhibit potent cholinesterase inhibition.
96
 Based on these 
observations, our objective was to consider other tricyclic systems to design small molecules 
with ability to target the cholinergic, amyloid and oxidative stress pathways of AD 
pathophysiology as disease-modifying agents. In this regard, we considered both phenothiazine 
and phenoselenazine based tricyclics (Figure 2.2). The fused tricyclic rings are anticipated to 
interact with the cholinesterase catalytic site whereas functionalization of N-10 with suitable 
pharmacophores could provide anti-amyloid aggregation properties unlike tacrine. In addition, it 
is known that both phenothiazines and phenoselenazines can act as antioxidants.
97
   
 
Figure 2.2: Proposed phenothiazines and phenoselenazines 
 22 
 
2.2 Phenothiazines (PTZ) 
 PTZs represent an important class of bioactive molecules. Currently they are used to treat 
various types of psychotic disorders.
98
 For example both chlorpromazine and fluphenazine are 
used in the clinical therapy as antipsychotic agents and exhibit dopamine receptor binding (D2-
antagonists) (Figure 2.3).
99
 In a recent study Darvesh and coworkers have shown that N-10-
carbonyl PTZs exhibit cholinesterase inhibition.
100
 In addition, PTZs are known to act as 
antioxidants due to their ability to accept unpaired electrons from ROS and form resonance 
stabilized PTZ radicals that are less reactive .
101
 The presence of a tricyclic ring system, 
chemically functionalizable N-10 and inherent antioxidant properties, support the design of PTZs 
as potential multi-targeting agents to treat AD. 
 
Figure 2.3: Chemical structures of chlorpromazine (1) and fluphenazine (2) 
2.3 Phenoselenazines (PSZ) 
PSZs are the selenium containing analogs of PTZs. Not much information is available on 
the biological properties of PSZs. Some early investigations on PSZs suggest that they exhibit 
similar antihistaminic and antipsychotic activity compared to their sulfur containing PTZ 
analogs.
102
 A recent patent describes the application of phenoselenazinium compounds as anti-
infective and anticancer agents.
103
 Furthermore, PSZs are known to exhibit antioxidant properties 
although the exact mechanisms are not clear. It plausible that similar to PTZs, they can form a 
resonance stabilized PSZ radical. In addition, the presence of selenium itself could provide 
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antioxidant properties. These characteristics support the development of PSZ as potential 
disease-modifying agents to treat AD. 
 
Figure 2.4: Chemical structures of some bioactive phenoselenazines (3) and (4) 
2.3.1 Selenium  
The trace element selenium (Se) is an essential micronutrient in the diet and is present in 
the amino acids selenocysteine and selenomethionine shown in Figure 2.5.
104, 105
 Furthermore, 
the hydroperoxide scavenging antioxidant enzyme GPx is a selenoprotein where the active site 
amino acid selenocysteine is known to scavenge ROS and prevent oxidative damage.
64
 Among 
the eight known GPx enzymes, GPx1 and GPx4 are known to provide neuroprotection in animal 
models of Parkinson’s and AD.106, 107 In addition, a recent study in AD patients indicated lower 
Se levels in the plasma, erythrocytes and nails compared to the control group suggesting that Se 
deficiency is a risk factor for AD.
108
 Accordingly, efforts are on to develop selenium-containing 
small molecules as GPx mimics to prevent neurodegeneration. In this regard, ebselen [2-phenyl-
1,2-benzisoselenazol-3(2H)-one, Figure 2.5] is a nontoxic organoselenium compound known to 
act as a GPx mimic and exhibits a number of pharmacological properties including antioxidant, 
anti-inflammatory, antiatherosclerotic, anticancer  and neuroprotective activities.
109-114
  Similar 
to glutathione, ebselen reacts with thiols to yield various organoselenium compounds. A key 
characteristic of ebselen is that each intermediate exhibits antioxidant activity, and that it is 
regenerated in a redox cycle making it an efficient compound in boosting the antioxidant defense 
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system. These studies indicate that selenium-based small molecules represent a promising class 
of agents to potentially treat AD.
 
 
Figure 2.5: Examples of selenium-containing biomolecules and compounds 
2.4 Conclusion 
 Fused tricyclic ring systems based on either a PTZ or a PSZ have the potential to serve as 
suitable ring templates to design novel small molecules to target multiple factors associated with 
AD pathophysiology including the cholinergic dysfunction, amyloid cascade and oxidative stress 
pathway. In this regard, the proposal aims to design novel PTZ and PSZ derivatives. The effect 
of steric and electronic properties on their biological properties are evaluated by varying 
substituents at the C-2 and N-10 position to acquire structure activity relationship (SAR) data. It 
is anticipated that the results will be provide useful insight into the design and development of 
novel tricyclics as disease-modifying agents with potential application to treat AD. 
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Chapter 3: Synthetic Chemistry  
3.1 Introduction 
 This chapter describes the synthetic strategies used to prepare PTZ and PSZ derivatives. 
Commercially available starting materials, unsubstituted phenothiazine and 2-
chlorophenothiazine were coupled to various acyl chlorides under mild conditions to obtain N-
acyl-PTZ derivatives whereas PSZ derivatives were prepared by coupling synthesized 
diphenylamines with selenium and selenium dioxide to obtain the PSZ template which was 
acylated to obtain N-acyl-PSZ derivatives. 
3.2 Proposal 
3.2.1 Synthesis of PTZ Derivatives 
The PTZ with either hydrogen or chlorine substituent at C-2 and various N-10 
substituents (benzoyl, phenylacetyl, hydrocinnamoyl, 3-methoxybenzoyl, 4-methoxybenzoyl and 
3,4-dimethoxybenzoyl) were synthesized.
115
 Figure 3.1 provides the chemical structures of PTZ 
derivatives synthesized.  
 
Figure 3.1: PTZ compound library synthesized 
 26 
 
3.2.2 Synthesis of PSZ Derivatives 
Selenium analogs of PTZ, namely, PSZ (15a-l) were also synthesized with either hydrogen or 
chlorine substituent at C-2 and various N-10 substituents (benzoyl, phenylacetyl, 
hydrocinnamoyl, 3-methoxybenzoyl, 4-methoxybenzoyl and 3,4-dimethoxybenzoyl).
115
 Figure 
3.2 provides the chemical structures of PSZ derivatives synthesized. 
 
 
 
 
 
 
 
 
 
Figure 3.2: PSZ compound library synthesized 
3.3 Results  
3.3.1. PTZ Derivatives 
 The N-acyl PTZ derivatives 7a-l were prepared by coupling either unsubstituted 
phenothiazine (5) or 2-chlorophenothiazine (6) with appropriate acyl chlorides (benzoyl, 
phenylacetyl, hydrocinnamoyl, 3-methoxybenzoyl, 4-methoxybenzoyl and 3,4-
dimethoxybenzoyl chlorides) in anhydrous toluene by refluxing overnight (Scheme 3.1). The 
PTZs were purified by flash chromatography and were characterized by 
1
H NMR and mass 
spectrometry. The yields ranged from 70-95%. 
 27 
 
 
Scheme 3.1: Synthesis of PTZ derivatives 7a-l 
3.3.2 PSZ Derivatives 
3.3.2.1 Diphenylamine (DPA) synthesis 
Aniline (8) or 3-chloroaniline (9), were coupled with phenylboronic acid to obtain either DPA 
(11) or 3-chloro DPA (12) respectively using a copper catalyst (Schemes 3.2 – 3.4),116-118 or by a 
2-step metal-free synthesis (Schemes 3.5 – 3.6).119, 120 The metal-free synthesis required the 
preparation of an α-iodinated cyclohex-2-ene (10). The DPA’s were obtained by aqueous work-
ups and purified by flash chromatography and characterized by 
1
H NMR and mass spectrometry. 
The yields ranged from 10 - 60%. 
 
Scheme 3.2: Copper-mediated synthesis of DPA (11), 3-Cl DPA (12) – method 1116 
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Scheme 3.3: Copper-mediated synthesis of DPA (11), 3-Cl DPA (12) – method 2117 
 
Scheme 3.4: Copper-mediated synthesis of DPA (11), 3-Cl DPA (12) – method 3118 
 
Scheme 3.5: Metal-free synthesis of DPA (11), 3-Cl DPA (12) – step 1, formation of an α-
iodinated cyclohex-2-ene (10)
119 
 
Scheme 3.6: Metal-free synthesis of DPA (11), 3-Cl DPA (12) – step 2120 
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3.3.2.2 Phenoselenazine (PSZ) synthesis  
Phenoselenazine (13) and 2-chlorophenoselenazine (14) was synthesized from DPA (11) or 3-Cl 
DPA (12) either from coupling with selenium monochloride
121
 or with selenium and selenium 
dioxide
122 
(Scheme 3.7 and 3.8 respectively). The respective phenoselenazines were purified by 
flash chromatography and characterized by 
1
H NMR and mass spectrometry. The yields ranged 
from 15 – 25%. 
 
Scheme 3.7: Phenoselenazine (13, 14) synthesis (method 1)
121 
 
Scheme 3.8: Phenoselenazine (13, 14) synthesis (method 2)
122 
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3.3.2.3 Synthesis of N-acyl-PSZ derivatives 
 The N-acyl PSZ derivatives 15a-l were prepared by coupling either unsubstituted 
phenothiazine (13) or 2-chlorophenothiazine (14) with appropriate acyl chlorides (benzoyl, 
phenylacetyl, hydrocinnamoyl, 3-methoxybenzoyl, 4-methoxybenzoyl and 3,4-
dimethoxybenzoyl chlorides) in anhydrous toluene by refluxing overnight (Scheme 3.9). The 
PTZs were purified by flash chromatography and were characterized by 
1
H NMR and mass 
spectrometry. The yields ranged from 30-95%. 
 
Scheme 3.9: Synthesis of PSZ derivatives 15a-l 
3.4 Mechanisms and Protocols 
3.4.1 PTZ Derivatives 
N-acyl PTZ derivatives 7a-l were prepared by coupling either unsubstituted phenothiazine (5) or 
2-chlorophenothiazine (6) with appropriate acyl chlorides (benzoyl, phenylacetyl, 
hydrocinnamoyl, 3-methoxybenzoyl, 4-methoxybenzoyl and 3,4-dimethoxybenzoyl chlorides) in 
anhydrous toluene by refluxing overnight (Scheme 3.1). The mechanism consisted of a 
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nucleophilic attack by the N-10 secondary amine of the PTZ leading to displacement of the 
chloride ion.  
 
 
 
 
 
 
 
Figure 3.3: General setup for the synthesis of PTZ derivatives 7a-l 
3.4.2 PSZ Derivatives 
3.4.2.1 Diphenylamine synthesis 
To either aniline (8) or 3-chloroaniline (9), phenylboronic acid was added, forming either 
diphenylamine (11) or 3-chloro diphenylamine (12) respectively. Various reaction conditions 
were tried. The first method involved a copper(II)-β-cyclodextrin complex added together with 
phenylboronic acid and aniline in water at room temperature (Scheme 3.2). The aqueous layer 
was then extracted with DCM and a subsequent column was run to purify the product. The use of 
the copper-(II)-β-cyclodextrin produces a metallic complex that acts as the reaction vessel, and 
the traditional oxidative addition, transmetallation and reductive elimination cycle is predicted to 
drive the reaction forward (Figure 3.4). 
 32 
 
 
Figure 3.4: A proposed mechanism of action for Scheme 3.2
116
 
The second and third method involved using copper acetate as the catalyst (Scheme 3.3 and 3.4). 
In Scheme 3.3, the reactants were added together with sodium carbonate and benzoic acid in 
EtOAc at rt. In Scheme 3.4, the reactants were added together with lutidine and myristic acid 
and refluxed at 80°C overnight. Upon completion both reaction mixtures were washed with 10% 
HCl and extacted with DCM, then purified by flash chromatography. Unlike the bulky 
cyclodextrin complex see in Figure 3.4, these two methods follow the traditional catalytic cycle 
seen. Initially, phenylboronic acid is coordinated to copper through transmetallation to form 
intermediate A. Coordination with aniline forms intermediate B, which then undergoes oxidation 
with dioxygen forming intermediate C. Through reductive elimination of C, the desired 
diphenylamine (11 or 12) is released, and copper is reduced at stage D. The last step regenerates 
the copper by oxidation with water forming complex E (Figure 3.5). 
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Figure 3.5: A proposed general mechanism of the copper-catalyzed DPA synthesis (Chan-Lam 
coupling) 
Another method used a metal-free approach towards the synthesis of diphenylamines (11 or 12) 
seen in Schemes 3.5 and 3.6. Preparation of the α-iodinated 2-cyclohex-2-enone (10) involved 
the addition of cyclohex-2-enone with iodine, using DMAP as a catalyst and potassium 
carbonate as a quenching agent in a 1:1 mixture of THF:H2O. The reaction mixture was diluted 
with EtOAc and washed with sodium thiosulfate and 10% HCl. The product was then purified by 
flash chromatography. The DMAP activates cyclohex-2-enone by attacking via a Michael 
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addition, forming a zwitterionic intermediate, hence the use of water to help in the stability of the 
intermediate. Through a subsequent nucleophilic attack to iodine, the α-iodinated intermediate is 
formed. The iodide ion liberates hydrogen iodide (HI) and regenerates DMAP (Figure 3.6). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6: Proposed mechanism of action for Scheme 3.5, synthesis of α-iodinated 2-cyclohex-
2-enone (10) 
The second step in the metal-free approach was the coupling of the α-iodonated 2-cyclohex-2-
enone (10) with either aniline (8) or 3-chloroaniline (9). The two starting materials were added 
together in EtOH with a stochiometric amount of p-TsOH (20 mol %) and refluxed overnight. 
The reaction mixture was then diluted with EtOAc and washed with 20% sodium bicarbonate 
and brine. The product was purified by flash chromatography. In an acidic environment the 
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primary amine attacks the eletrophilic carbonyl, through subsequent protonation/de-protonation 
steps water is eliminated and the nitrogen replaces the oxygen forming the imine/enamine 
tautomerization pair. While in the enamine form, a hydride shift occurs, allowing the iodine to be 
eliminated in the form of HI, thus forming the final product (Figure 3.7). 
 
Figure 3.7: Proposed mechanism of scheme 3.6, the second step of the metal-free approach 
The general sequence of steps used in the preparation of DPA (11 and 12) is given in Figure 3.8. 
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Figure 3.8: General setup for the synthesis of DPA (11) or 3-chloro DPA (12) 
3.4.2.2 Phenoselenazine (PSZ) synthesis 
Phenoselenazine (13) and 2-chlorophenoselenazine (14) was synthesized from DPA (11) or 3-Cl 
DPA (12) either from coupling with selenium monochloride
 
(Scheme 3.7) or with selenium and 
selenium dioxide (Scheme 3.8). In Scheme 3.7, the source of selenium was selenium 
monochloride which was added with either DPA (11) or 3-Cl DPA (12) in DCM, refluxing for 6 
hrs. In Scheme 3.8 the source of selenium was selenium metal (limiting reagent). It is consumed 
and converted to hydrogen selenide. In an attempt to maximize yield, selenium dioxide was 
added to help regenerate selenium metal in-situ in the presence of hydrogen selenide (Figure 
3.9). 
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Figure 3.9: In-situ regeneration of selenium for Scheme 3.8 
Selenium metal, thus was added with selenium dioxide and iodine in sulpholane and placed in a 
PV in an oil bath at 150 °C for 5 hrs. Both reaction mixtures were cooled and filtered in DCM 
plugs of celite and purified by flash chromatography. The proposed reaction mechanism is 
similar for both schemes, in Scheme 3.7, selenium is already coordinated with chloride, and 
Scheme 3.8 has the catalytic iodine coordinating with selenium. The selenium then acts as the 
electrophile, and through a sequential nucleophilic aromatic substitution, the core PSZ structure 
is closed off (Figure 3.10). Figure 3.11 highlights the general setup for these two schemes. 
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Figure 3.10: Proposed mechanism for the synthesis of phenoselenazine (13) and 2-
chlorophenoselenazine (14) 
 
Figure 3.11: General setup for synthesis of phenoselenazine (13) and 2-chlorophenoselenazine 
(14) 
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3.4.2.3 Synthesis of N-acyl-PSZ derivatives 
Similar to that of the PTZ series (7a-l), the N-acyl PSZ derivatives 15a-l were prepared by 
coupling either unsubstituted phenoselenazine (13) and 2-chlorophenoselenazine (14) with 
appropriate acyl chlorides (benzoyl, phenylacetyl, hydrocinnamoyl, 3-methoxybenzoyl, 4-
methoxybenzoyl and 3,4-dimethoxybenzoyl chlorides) in anhydrous toluene by refluxing 
overnight (Scheme 3.9). The PSZs were purified by flash chromatography. The mechanism 
consisted of a nucleophilic attack by the secondary amine of the PSZ leading to the displacement 
of the chloride ion to form N-acyl PSZ derivaties. 
 
 
 
 
 
 
 
 
Figure 3.12: General setup for the synthesis of PSZ derivatives 15a-l 
3.5 Conclusion 
The synthesis of PTZ derivatives (7a-l) were straightforward as starting precursors were readily 
available. The synthesis of PSZ was achieved in 3 steps (i) synthesis of DPA (11) or 3-Cl DPA 
(12) (ii) synthesis of phenoselenazine (13) and 2-chlorophenoselenazine (14) and (iii) N10 
coupling to obtain PSZ derivatives 15a-l. A total of 26 compounds were synthesized and 
characterized as potential anti-AD agents. 
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Chapter 4: Biological Evaluation  
4.1 Introduction 
 The biological activities of synthesized PTZ derivatives 7a-l and PSZ derivatives 15a-l 
were evaluated using a number of assay protocols including human cholinesterase inhibition 
(using both AChE and BuChE), anti-amyloid aggregation assay using Aβ1-42 peptide, antioxidant 
assay and cell viability/toxicity assay at various compound concentrations.  This chapter 
describes the assay principles, structure activity relationship (SAR) data acquired and discusses 
the ability of PTZ and PSZ derivatives to target multiple factors associated with AD 
pathophysiology.   
4.2 Human Cholinesterase Inhibition Studies 
4.2.1 Assay Principle 
The cholinesterase (ChE) screening assay is based on Ellman’s method, a standard method in 
testing the inhibition of both acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE).
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The colorimetric assay utilizes thio-ester analogs of acetylcholine (ACh) and butyrylcholine 
(BuCh) as the substrate, which when hydrolyzed to their free-thiol form reacts with 5,5'-
dithiobis-(2-nitrobenzoic acid) (DTNB) to form a yellow chromophore at 405-412 nm (Figure 
4.1). From the compound screening, ChE inhibition profiles were obtained through the 
monitoring of the chromophore formed by UV spectroscopy. Known ChE inhibitors, tacrine, 
donepezil and galantamine were used as reference agents for comparison.  
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Figure 4.1: Cholinesterase assay principle 
4.3 Results and Discussion 
4.3.1 PTZ Derivatives SAR 
The unsubstituted PTZ’s (5 and 6) and its derivatives 7a-l, were evaluated for their ability 
to inhibit both human AChE and BuChE enzymes. Their activity was compared to known 
cholinesterase inhibitors tacrine, donepezil and galantamine (Table 4.1). The unsubstituted PTZ 
derivative 5 exhibited an IC50 value of 7.37 µM towards human AChE and was less potent 
compared to reference agents tacrine (AChE IC50 = 0.16 µM), donepezil (AChE IC50 = 0.04 µM) 
and galantamine (AChE IC50 = 2.60 µM). Addition of an N-benzoyl substituent in compound 7a 
retained AChE inhibition (IC50 = 8.10 µM) and the compound was less potent compared to 5. 
The effect of aromatic acyl groups with one (benzyl) and two carbon spacer (phenethyl) on 
AChE inhibition were explored (compounds 7b and 7c). These modification provided AChE 
inhibition and both compounds 7b (AChE IC50 = 7.40 µM) and 7c (AChE IC50 = 7.15 µM) 
exhibited similar activity as compared to 5 (AChE IC50 = 7.37 µM) although they were less 
potent compared reference agents. Our previous work has shown that the presence of a 3,4-
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dimethoxyphenyl substituent provided good cholinesterase inhibition.
96
 Accordingly the effect of 
methoxyphenyl substituents was explored by evaluating compounds 7d-f (Table 4.1). 
Interestingly, these compounds exhibited AChE inhibition ranging from 5.80 to 6.20 µM (IC50s) 
and were more potent compared to compounds 5 and 7a-c. The 3,4-dimethoxybenzoyl 
compound (7f) was identified as the most potent AChE inhibitor (IC50 = 5.80 µM). Furthermore, 
the addition of C-2 chlorine to the PTZ scaffold was investigated. It appears that C-2 chlorine 
substituent was not a major factor in AChE inhibition and C-2 chloro-PTZ derivatives 7g-l 
exhibited IC50 values in the range of 4.67 to 10.0 µM (Table 4.1). Similar to the compounds 
from the nonchlorinated PTZ series (5 and 7a-c), the presence of methoxybenzoyl substituents 
enhanced AChE inhibition (7j-l) with compound 7k (3-methoxybenzoyl) identified as the most 
potent compound (AChE IC50 = 4.67 µM) among the C-2 chloro-PTZ derivatives. 
The SAR studies of PTZs on BuChE inhibition indicates that they were generally weak 
inhibitors and were less potent compared to their inhibitory potency towards AChE (Table 4.1). 
Among the nonchlorinated PTZs including 5 and 7a-f, compound 5 exhibited superior inhibitory 
potency (BuChE IC50 = 5.80 µM) relative to AChE (IC50 = 7.37 µM) and was the most potent. It 
was approximately 11-fold more potent relative the reference agent galantamine (BuChE IC50 = 
66.50 µM) and was less potent compared to both tacrine (BuChE IC50 = 0.04 µM) and donepezil 
(BuChE IC50 = 3.60 µM). Among the 2-Cl-PTZ derivatives 7g-l, compound 7h with a 
phenylacetyl substituent was identified as the most potent BuChE inhibitor (BuChE IC50 = 3.60 
µM). In general, the presence of a 2-Cl substituent led to enhanced BuChE inhibition potency for 
N-acyl PTZ derivatives 7g-l relative to the corresponding nonchlorinated N-acyl PTZ derivatives 
7a-f. Interestingly, the presence of either a ethylphenyl (7i) or 4-methoxybenzoyl (7k) N-acyl 
substituents provided similar BuChE inhibition (IC50 values of 5.0 and 5.30 µM respectively) 
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whereas both 3-methoxyphenyl (7j) and 3,4-dimethoxyphenyl (7l) derivatives exhibited weak 
inhibition (IC50 values of 30.80 and 32.66 µM respectively). Figure 4.2 highlights the effects of 
the chlorine on BuChE inhibition, with the general trend that adding C-2 chlorine led to 
enhanced BuChE potency. 
 
Figure 4.2: Graphical summary of chlorine’s effect on BuChE inhibition of PTZ series. Results 
are expressed as average ± SD (n = 3) of two independent experiments. Error bars represent 
standard deviation 
The cholinesterase SAR study for PTZ compound library, demonstrates that they exhibit 
dual inhibition of both AChE and BuChE enzymes. Their AChE inhibition ranged from 4.67-
10.0 µM (IC50s) whereas their BuChE inhibition ranged from 3.60-110.50 µM. Compounds 
exhibited nonselective inhibition of both the enzymes and generally exhibited superior AChE 
inhibition potency. These studies show that PTZ derivatives serve as useful ring scaffolds to 
design dual cholinesterase inhibitors. 
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Table 4.1: Cholinesterase inhibition data, Selectivity Index and ClogP values of PTZ series 
 
________________________________________________________________________ 
Compd R   IC50 (µM)
a
  Selectivity   ClogP
c
   
            AChE BuChE   Index (SI)
b
 
____________________________________________________________________________ 
5  -   7.37 5.80       1.27  3.56 
7a  Phenyl   8.07 110.52       0.07  5.23  
7b  Benzyl   7.41 38.35       0.19  3.87 
7c  Phenethyl  7.14 51.00       0.14  4.20 
7d  4-Methoxyphenyl 6.31 53.06       0.12  5.45 
7e  3-Methoxyphenyl 6.23 25.50       0.24  5.45 
7f  3,4-Dimethoxyphenyl 5.81 45.02       0.13  4.59 
6  -   7.39 19.19       0.39  4.59 
7g  Phenyl   9.97 9.34       0.52  6.00 
7h  Benzyl   7.51 3.64       2.06  4.64 
7i  Phenethyl  7.92 5.02       1.58  4.97 
7j  4-Methoxyphenyl 5.89 5.35       1.10  6.22 
7k  3-Methoxyphenyl 4.67 30.84       0.15  6.22 
7l  3,4-Dimethoxyphenyl 6.41 32.65       0.20  5.90 
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Tacrine  -  0.16 0.04       4.00  2.27 
Donepezil  -  0.04 3.60       0.01  4.60 
Galantamine  -  2.59 66.50       0.04  1.02 
______________________________________________________________________________ 
a
IC50 values are average of two to three independent experiments (n = 3) with deviation <10% of 
mean value. 
b
SI = hBuChE/hAChE IC50. 
c
ClogP was determined using ChemDraw Ultra version 
11.0 Cambridge Software Company.  
 
4.3.2 PSZ Derivatives SAR 
The unsubstituted PSZ’s (13 and 14) and its derivatives 15a-l, were evaluated for their 
ability to inhibit both human AChE and BuChE enzymes. Their activity was compared to known 
cholinesterase inhibitors tacrine, donepezil, galantamine and ebselen (Table 4.2). The 
unsubstituted PSZ derivative 13 exhibited an IC50 value of 5.63 µM towards human AChE and 
was less potent compared to reference agents tacrine (AChE IC50 = 0.16 µM), donepezil (AChE 
IC50 = 0.04 µM) and galantamine (AChE IC50 = 2.60 µM). However, it showed greater potency 
than the organoselenium compound ebselen (AChE IC50 = 6.24 µM). Addition of an N-benzoyl 
substituent in compound 15a retained AChE inhibition (IC50 = 5.43 µM) and the compound was 
more potent compared to 13. Again, the effect of aromatic acyl groups with one (benzyl) and two 
carbon spacer (phenethyl) on AChE inhibition were explored (compounds 15b and 15c). These 
modification provided AChE inhibition and both compounds 15b (AChE IC50 = 6.41 µM) and 
15c (AChE IC50 = 6.76 µM) exhibited less potency as compared to 13 (AChE IC50 = 5.63 µM). 
The effect of methoxyphenyl substituents was explored by evaluating compounds 15d-f (Table 
4.2). Interestingly, these compounds exhibited AChE inhibition ranging from 4.62 to 6.25 µM 
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(IC50) and were more potent compared to compounds 13 and 15a-c with the exception of 15k 
(AChE IC50 = 6.25 µM). The 4-dimethoxyphenyl compound (15d) was identified as the most 
potent AChE inhibitor (IC50 = 4.63 µM). Furthermore, the addition of C-2 chlorine to the PSZ 
scaffold was investigated. Similar to the PTZ series, the C-2 chlorine substituent was not a major 
factor in AChE inhibition and C-2 chloro-PSZ derivatives 15g-l exhibited IC50 values in the 
range of 5.79 to 6.58 µM (Table 4.2). Similar to the compounds from the nonchlorinated PSZ 
series (13 and 15a-c), the presence of methoxyphenyl substituents enhanced AChE inhibition 
(15j-l) with compound 15j (4-methoxyphenyl) identified as the most potent compound (AChE 
IC50 = 5.79 µM) among the C-2 chloro-PTZ derivatives. 
The SAR studies of PSZs on BuChE inhibition indicates that they were generally weak 
inhibitors and were less potent compared to their inhibitory potency towards AChE (Table 4.2). 
Among the nonchlorinated PSZs including 13 and 15a-f, compound 13 exhibited superior 
inhibitory potency (BuChE IC50 = 3.00 µM) relative to AChE (IC50 = 5.63 µM) and was the most 
potent. It was approximately 22-fold more potent relative the reference agent galantamine 
(BuChE IC50 = 66.50 µM), more potent than donepezil (BuChE IC50 = 3.6 µM) and ebselen 
(BuChE IC50 = 4.65 µM) and was less potent compared to both tacrine (BuChE IC50 = 0.04 µM). 
Among the 2-Cl-PTZ derivatives 15g-l, compound 15g with a benzoyl substituent was identified 
as the most potent BuChE inhibitor (BuChE IC50 = 3.88 µM). In general, the presence of a 2-Cl 
substituent led to enhanced BuChE inhibition potency for N-acyl PSZ derivatives 15g-l relative 
to the corresponding nonchlorinated N-acyl PSZ derivatives 15a-f, with the exception of the 3-
methoxyphenyl compound (15k) which gave a 2-fold decrease in potency (BuChE IC50 = 19.30 
µM). Interestingly, the presence of either a 4-methoxybenzoyl (15j) or and 3,4-
dimethoxybenzoyl (15l)  N-acyl substituents provided similar BuChE inhibition (IC50 values of 
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4.91 and 5.75 µM respectively) whereas both 3-methoxyphenyl (15k) and phenethyl (15i) 
derivatives exhibited weak inhibition (IC50 values of 40.00 and 19.30 µM respectively). Figure 
4.3 highlights the effects of the chlorine on BuChE inhibition, with the general trend that adding 
the chlorine led to enhanced BuChE potency similar to the PTZ series. 
 
Figure 4.3: Graphical summary of chlorine’s effect on BuChE inhibition of PSZ series. Results 
are expressed as average ± SD (n = 3) of two independent experiments. Error bars represent 
standard deviation 
The cholinesterase SAR study for PSZ compound library, demonstrates that they exhibit 
dual inhibition of both AChE and BuChE enzymes. Their AChE inhibition ranged from 4.63-
6.76 µM (IC50s) whereas their BuChE inhibition ranged from 3.88-39.73 µM. Similar to that of 
the PTZ series, the PSZ series exhibited nonselective inhibition of both the enzymes and 
generally exhibited superior AChE inhibition potency. These studies show that PSZ derivatives 
serve as useful ring scaffolds to design dual cholinesterase inhibitors. 
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Table 4.2: Cholinesterase inhibition data, Selectivity Index and ClogP values of PSZ series 
 
____________________________________________________________________________ 
Compd R   IC50 (µM)
a
  Selectivity   ClogP
c
   
            AChE BuChE   Index (SI)
b
 
____________________________________________________________________________ 
13  -   5.63 3.00       1.90  4.36 
15a  Phenyl   5.43 22.75       0.24  6.03  
15b  Benzyl   6.41 11.05       0.58  4.67 
15c  Phenethyl  6.76 38.00       0.18  5.00 
15d  4-Methoxyphenyl 4.63 11.14       0.42  6.25 
15e  3-Methoxyphenyl 6.25 9.63       0.65  6.25 
15f  3,4-Dimethoxyphenyl 5.10 9.09       0.56  5.93 
14  -   6.34 4.75       1.33  5.37 
15g  Phenyl   6.04 3.88       1.56  6.74 
15h  Benzyl   6.58 5.02       1.31  5.38 
15i  Phenethyl  6.29 40.00       0.16  5.72 
15j  4-Methoxyphenyl 5.79 4.91       1.18  6.96 
15k  3-Methoxyphenyl 5.92 19.30       0.03  6.96 
15l  3,4-Dimethoxyphenyl 6.18 5.75       1.07  6.64 
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Tacrine  -  0.16 0.04       4.00  2.27 
Donepezil  -  0.04 3.60       0.01  4.60 
Galantamine  -  2.59 66.47       0.04  1.02 
Ebselen  -  6.24 4.65       1.34  3.70 
______________________________________________________________________________ 
a
IC50 values are average of two to three independent experiments (n = 3) with deviation <10% of 
mean value. 
b
SI = hBuChE/hAChE IC50. 
c
ClogP was determined using ChemDraw Ultra version 
11.0 Cambridge Software Company.  
 
4.4 Conclusion 
Both the PTZ and PSZ scaffolds serve as viable core templates as dual cholinesterase 
inhibitors. Among the PTZ derivatives, compound 7k was indentified as the most potent AChE 
inhibitor (AChE IC50 = 4.67 µM); compound ; compound 7j as the best dual ChE inhibitor 
(AChE IC50 = 5.89 µM, BuChE IC50 = 5.35 µM); and compound 7h as the best BuChE inhibitor 
(BuChE IC50 = 3.64 µM). This indicates that N-acylation enhances ChE inhibition compared to 
the unsubstituted PTZ’s 5 and 6. Among the PSZ derivatives, compound 15d was identified as 
the most potent AChE inhibitor (AChE IC50 = 4.63 µM); compound 15g as the best dual ChE 
inhibitor (AChE IC50 = 5.79 µM, BuChE IC50 = 4.91 µM); and compound 13 as the best BuChE 
inhibitor (BuChE IC50 = 3.88 µM). This indicates that N-acylation enhances ChE inhibition 
compared to the unsubstituted PSZ’s 13 and 14. The electronic effect of adding a chlorine at the 
2-position of the PTZ and PSZ scaffold helped increase its potency towards BuChE greatly 
without loss of AChE activity. The best compounds are highlighted below in Figures 4.4 and 4.5. 
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Figure 4.4: Top candidates from the PTZ series from cholinesterase inhibition 
 
Figure 4.5: Top candidates from the PSZ series from cholinesterase inhibition 
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4.5 Amyloid Aggregation Inhibition Studies 
4.5.1 Assay Principle 
The Aβ aggregation assay is based on the biophysical properties that amyloid (Aβ) peptides 
exhibit. Thioflavin T (ThT), a fluorescent dye was used. Its fluorescence is monitored, and the 
change in fluorescence is detected when ThT is bound within the cross β-sheet formation 
(Figure 4.6). Normally ThT exhibits fluorescence at 446 nm but when bound to the rigid 
structures of Aβ there is a characteristic red shift, at 490 nm. From the compound screening, the 
relative fluorescence units (RFU) are monitored over a 16 hour period.
124
 The compounds with 
anti-amyloid aggregation properties promote more free unbound ThT, and this is indicated by the 
lower RFU values at 490 nm ThT emission wavelength. 
 
Figure 4.6: Anti-amyloid aggregation assay principle 
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4.6 Results and Discussion 
4.6.1 PTZ Derivatives SAR 
The unsubstituted PTZ’s (5 and 6) and their 3,4-dimethoxybenzoyl derivative (7f) was evaluated 
for their ability to inhibit self-induced Aβ1-42 aggregation at four different concentrations (1, 5, 
10 and 25 µM). Their activity was compared to known aggregation inhibitor, orange G (Table 
4.3). The unsubstituted PTZ (5) exhibited superior anti-aggregation activity compared to 
reference orange G at all concentrations. 7f was also screened, but showed weak anti-aggregation 
potency (< 4% aggregation inhibition at all concentrations). Similarly, the 2-chloro analogs 6, 
and 7l were also screened and the unsubstitued 2-chloroPTZ (6) showed a lower degree of anti-
aggregation property at 1, 5, and 10 µM compared to 5. At 25 µM both 5 and 6 exhibited similar 
anti-aggregation properties. (61.9 and 60.8% aggregation inhibition respectively). Compound 6 
exhibited comparable anti-aggregation activity to control orange G, showing similar percent 
inhibition across each concentration. The chlorinated 3,4-dimethoxybenzoyl compound (7l) 
again showed poor inhibition values at each concentration of 1, 5, 10 and 25 µM (6.2, 4.5, 6.5, 
5.9% aggregation inhibition respectively) indicating that the activity was independent of 
concentration. It appears that for PTZ derivaties, N-acylation was detrimental to anti-aggregation 
activity with both the unsubstituted compounds 5 and 6 exhibiting superior anti-aggregation 
properties. Figure 4.7 shows the aggregation kinetics of compound 5. In the absence of 
compound 5, a typical Aβ aggregation curve is seen (100% control) with an initial lag phase that 
corresponds to nucleation dependent aggregation, followed by a rapid growth phase and a 
saturation phase corresponding to Aβ fibril formation. Increasing the concentration of compound 
5 was clearly able to reduce the formation of Aβ fibrils by affecting the growth and saturation 
phase. 
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Table 4.3: Self-induced amyloid (Aβ1-42) inhibition data for PTZ derivatives 
 
________________________________________________________________________ 
Compd R    X   % Inhibition at:
a
  
                 1 µM 5 µM 10 µM 25 µM 
________________________________________________________________________ 
5  H    H  18.3 37.2 59.1 61.9 
7f  3,4-Dimethoxybenzoyl H  NA NA NA NA 
6  H    Cl  10.3 22.0 33.7 60.8 
7l  3,4-Dimethoxybenzoyl Cl  6.2 4.5 6.5 5.9 
Orange G -    -  8.6 20.4 31.0 57.2 
________________________________________________________________________ 
a
Percent aggregation inhibition values are average ± s.d < 10% (n = 3) for two independent 
experiments. NA = not active, % inhibition < 4% 
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Figure 4.7: Aβ1-42 aggregation kinetic data for compounds 5 at 37 
◦
C, 16 hr incubation in sodium 
phosphate buffer at pH 8.5 
 
4.6.2 PSZ Derivatives SAR 
The unsubstituted PSZ’s (13 and 14) and its 3,4-dimethoxybenzoyl derivative (15f) was 
evaluated for their ability to inhibit self-induced Aβ1-42 aggregation at four different 
concentrations (1, 5, 10 and 25 µM). Their activity was compared to known aggregation inhibitor, 
orange G (Table 4.4). At the lower concentrations of 1 and 5 µM, the unsubstituted PSZ (13) 
(16.3 and 24.1% aggregation inhibition respectively) exhibited superior anti-aggregation activity 
compared to reference orange G (8.6 and 20.4% aggregation inhibition respectively). However, it 
was less potent at 25 µM (45.55%, 13 vs 57.24%, orange G). 15f was also screened and showed 
a 3-4 fold decrease in anti-aggregation potency compared to 13 at each concentration. Similarly, 
the 2-chloro analogs 14, and 15l were also screened. The unsubstitued 2-chloroPSZ (14) showed 
similar anti-aggregation activity relative to 13 at all concentrations (Table 4.4). At 1 µM 14 
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(14.50% aggregation inhibition) exhibited greater anti-aggregation activity compared to orange 
G (8.63% aggregation inhibition), but showed decreased activity at higher concentrations. The 
chlorinated 3,4-dimethoxybenzoyl compound (15l) version showed poor inhibition values at 
each concentration of 1, 5, 10 and 25 µM (8.4, 7.9, 9.1, 5.9% aggregation inhibition respectively). 
The most potent anti-aggregation compound was the unsubstituted PSZ (13), showing that N-
acylation was detrimental to anti-aggregation activity. The aggregation kinetic profile for 13 
(Figure 4.8) shows that it was able to decrease Aβ fibril formation with increasing concentration. 
It affected both the growth and saturation phase of Aβ fibril formation similar to the PTZ 
bioisostere 5. 
Table 4.4: Self-induced amyloid (Aβ1-42) inhibition data for PSZ derivatives 
 
________________________________________________________________________ 
Compd R    X   % Inhibition at:
a
  
                 1 µM 5 µM 10 µM 25 µM 
_______________________________________________________________________ 
13  H    H  16.3 24.1 30.7  45.6 
15f  3,4-Dimethoxybenzoyl H  6.3 5.7 8.7 11.1 
14  H    Cl  14.5 18.5 25.1 45.0 
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15l  3,4-Dimethoxybenzoyl Cl  8.4 7.9 9.1 5.9 
Orange G -    -  8.6 20.4 31.0 57.2 
________________________________________________________________________ 
a
Percent aggregation inhibition Values are average ± s.d < 10% (n = 3) for two independent 
experiments. 
 
Figure 4.8: Aβ1-42 aggregation kinetic data for compounds 13 and at 37 
◦
C, 16 hr incubation 
sodium phosphate buffer at pH 8.5 
4.7 Conclusion 
The non-acylated PTZ (5) and PSZ (13) compounds exhibited good anti-aggregation properties 
compared to N-acylated derivatives. The addition of the 3,4-dimethoxybenzoyl substituent  to 
both un-chlorinated and chlorinated derivatives led to poor anti-aggregation properties. The 
unsubstituted PTZ (5) showed superior inhibition compared to other compounds screened 
including the reference agent, orange G. 
0 
200 
400 
600 
800 
1000 
1200 
1400 
1600 
0 200 400 600 800 1000 
R
e
la
ti
ve
 F
lu
o
re
sc
e
n
ce
 U
n
it
s 
(R
.F
.U
.s
) 
Time (min) 
Self-induced Amyloid 1-42 inhibition Profile of 
PSZ 
1 µM 
5 µM 
10 µM 
25 µM 
ThT 
100 Abeta 
 57 
 
 
Figure 4.9: Chemical structures of top compounds with anti-Aβ1-42 aggregation activity 
4.8 Antioxidant Assay 
4.8.1 Assay Principle 
The anti-oxidant assay measures the compounds ability to scavenge free radicals. The 2,2-
diphenyl-1-picrylhydrazyl radical (•DPPH) is a well-known standard used to measure antioxidant 
properties. It acts as a stable free radical due to the electron delocalization around the molecule, 
which exhibits a deep purple solution and strong absorption at 517 nm. When it gets neutralized 
with an anti-oxidant source, the solution becomes a pale yellow (Figure 4.10). The monitoring 
of the change in absorbance at 517 nm allows for measurement of antioxidant activity.
125
 
 
Figure 4.10: DPPH radical scavenging assay principle 
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4.9 Results and Discussion 
4.9.1 PTZ Derivatives SAR 
The antioxidant properties of some representative compounds from the PTZ library was 
evaluated using DPPH assay and the results were compared with reference agent ebselen and 
trolox (Table 4.5).  The basic PTZ template (5) exhibited potent antioxidant activity at 50 µM 
(92% inhibition) and its antioxidant activity was similar to trolox (96% inhibition). The addition 
of a C-2 chloro substituent in 6 reduced the antioxidant property (76% inhibition). Interestingly, 
acylation of the PTZ N-10 led to a dramatic decline in their ability to scavenge DPPH radical. 
For example both compounds 7f and 7l with 3,4-dimethoxybenzoyl N-acyl substituents exhibited 
44 and 46% inhibition at 50 µM (Table 4.6) and were less potent compared to the non-acylated 
compounds 5 and 6. These results indicate that the presence of a free NH group plays an 
important role in DPPH scavenging ability. Nevertheless N-acylation did not abolish antioxidant 
properties altogether and compounds 7f and 7l did retain antioxidant properties which indicates 
that N-acylated PTZ derivatives can be considered as suitable systems to design multifunctional 
agents to target the oxidative stress hypothesis of AD pathophysiology. 
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Table 4.5: DPPH radical scavenging by PTZ derivatives 
 
____________________________________________________________________ 
Compd  R    X % Inhibition at 50 µM
a 
____________________________________________________________________ 
 5   H     H  92.1  
 7f   3,4-Dimethoxybenzoyl H  44.3 
 6   H     Cl  76.4 
 7l   3,4-Dimethoxybenzoyl Cl  46.5 
 Trolox   -    -  99.2 
___________________________________________________________________ 
a
Percent inhibition values are average of two independent experiments (n = 3) with deviation <10% 
of mean value. 
4.9.2 PSZ Derivatives SAR 
The ability of PSZs to scavenge DPPH radical was evaluated. Unsubstituted PSZ (13), 2-
Cl-PSZ (14) and N-acyl PSZ derivatives (15f and 15l) were evaluated (Table 4.6). The trend 
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obtained was similar to PTZ series. PSZs with a free NH group exhibited potent antioxidant 
activity (compound 13, 84% inhibition and compound 14, 73% inhibition at 50 µM). Both 
compounds were much more potent compared to the selenium containing reference agent ebselen 
(33% inhibition) although were less potent compared to trolox (96% inhibition). The presence of 
an electron withdrawing C-2 chlorine group in compound 14, reduced its ability to scavenge 
DPPH radical compared to the non-chlorinated PSZ compound 13. The N-acylated PSZ 
derivatives with a 3,4-dimethoxybenzoyl substituents (compound 15f  and 15l) exhibited reduced 
activity (39 and 38% inhibition respectively) with almost 2.2-fold reduction in their ability to 
scavenge DPPH radical relative to the non-acylated compound 13 (84% inhibition). These 
studies indicate that N-acyl PSZ derivatives exhibit antioxidant properties and represent a useful 
template in the design of multi-targeting agents with antioxidant properties to treat AD. 
Table 4.6: DPPH radical scavenging by PSZ derivatives 
 
____________________________________________________________________ 
Compd  R    X % Inhibition at 50 µM
a 
____________________________________________________________________ 
 13   H    H  84.4    
 15f   3,4-Dimethoxybenzoyl H  39.0 
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 14   H    Cl  73.2 
 15l   3,4-Dimethoxybenzoyl Cl  38.3 
 Trolox   -    -  99.2 
 Ebselen  -    -  34.7 
__________________________________________________________________ 
a
Percent inhibition values are average of two independent experiments (n = 3) with deviation <10% 
of mean value. 
4.10 Conclusion 
The DPPH based antioxidant screen for PTZ and PSZ compounds demonstrates that both 
class of tricyclics exhibit antioxidant properties. The study also shows that the presence of a free 
amine (N-10) provides excellent antioxidant properties whereas N-acyl substitution can lead to a 
reduction in their DPPH scavenging ability. This could be due to the fact that non-acylated PTZ 
and PSZ’s with a free NH group could be more efficient scavengers of DPPH radicals due to the 
formation of a resonance stabilized radical (Figure 4.11) whereas N-acylation might compromise 
this stability leading to a reduction in the antioxidant properties. It should be noted that selenium 
metal itself is known to exhibit antioxidant properties suggesting that in vivo metabolites of PSZ 
derivatives have the potential to exhibit antioxidant properties.
112, 113
 These studies show that 
both PTZ and PSZ derivatives exhibit antioxidant properties and could serve as bioisosteres in 
the design of novel tricyclics as potential disease modifying agents to treat AD. The two best 
antioxidant compounds are highlighted in Figure 4.12.     
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Figure 4.11 Mechanism of PTZ and PSZ based antioxidants 
 
 
Figure 4.12: Chemical structures of top PTZ and PSZs with antioxidant properties 
4.11 Evaluation of Cell Viability 
4.11.1 Assay Principle 
The cell viability assay for some PTZ and PSZ derivatives were carried out to evaluate their 
toxicity. By using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) and the 
activity of the mitochondrial reductase in metabolically active cells, the cytotoxic effects of test 
compounds can be quantified.
126
 MTT is a yellow tetrazole that is reduced to a purple formazan 
in living cells (Figure 4.13). The monitoring of the absorbance of the formazan at 570 nm allows 
for the measurement of cell viability. Compounds with reduced cytotoxicity do not affect 
formazan reduction by living cells. 
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Figure 4.13: MTT based cell viability assay principle 
 
4.12 Results and Discussion 
4.12.1 PTZ Derivatives  
The unsubstituted PTZ’s (5 and 6) and its 3,4-dimethoxy derivatives (7f and 15f) were evaluated 
for their viability towards the SH-SY5Y neuroblastoma cell line at 50 µM (Table 4.7). The 
unsubstituted PTZ (5) (63.72% cell viability) exhibited moderate to good tolerance by the 
neuroblastoma cells. The 7f derivative was also screened and showed similar tolerance. (64.4% 
cell viability) Similarly, the 2-chloro analogs 6, and 7l were also screened. The unsubstitued 2-
chloroPTZ (6) (64.0% cell viability) showed comparable values to both 5 and 7l. Interestingly, 
the 3,4-dimethoxybenzoyl group in the chlorinated (7l) version was identified as a PTZ 
derivative with good cell viabilty (71.6% cell viability). 
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Table 4.7: Percent viability of SH-SY5Y cell line after treatment with PTZs 
 
_________________________________________________________________ 
Compd R    X % Cell viability at 50 µM
a 
_________________________________________________________________ 
 5  H     H   63.7  
 7f  3,4-Dimethoxybenzoyl H   64.4 
 6  H     Cl   64.0 
 7l  3,4-Dimethoxybenzoyl Cl   71.6 
_________________________________________________________________ 
a
Percent inhibition values are average of two independent experiments (n = 3) with deviation <10% 
of mean value. 
4.12.2 PSZ Derivatives  
The unsubstituted PSZ (13 and 14) and its 3,4-dimethoxy derivatives (15f and 15l) was evaluated 
for their viability towards the SH-SY5Y neuroblastoma cell line at 50 µM. Their activity was 
compared to known organoselenium compound, ebselen. (Table 4.8) The unsubstituted PSZ (13) 
(76% cell viability) exhibited better tolerance compared to ebselen (59.3% cell viability). The 
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15f derivative was also screened and showed an even higher tolerance. (93.69% cell viability) 
The 2-chloro analogs 14, and 15l were also screened. The unsubstitued 2-chloroPSZ (14) (43.0% 
cell viability) showed a decrease in cell viability. Interestingly, the chlorinated 3,4-
dimethoxybenzoyl compound (15l) exhibited the best tolerance (100% cell viability). 
Table 4.8:  Percent viability of SH-SY5Y cell line after treatment with PSZs 
 
_________________________________________________________________ 
Compd R    X % Cell viability at 50 µM
a 
_________________________________________________________________ 
 13  H    H   76.0 
 15f  3,4-Dimethoxybenzoyl H   93.7 
 14  H    Cl   43.0 
 15l  3,4-Dimethoxybenzoyl Cl   100 
 Ebselen -    -   59.3 
_________________________________________________________________ 
a
Percent inhibition values are average of two independent experiments (n = 3) with deviation <10% 
of mean value. 
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4.13 Conclusion 
The MTT cell viability assay performed on the PTZ and PSZ series demonstrated moderate to 
good cell viability at 50 µM in SH-SY5Y neuroblastoma cell line. The PTZ series showed 
moderate cell viability (63.7-71.6% cell viability). In the PSZ series, the unsubstituted derivates 
showed similar results to the PTZ derivates (43.0-76.0% cell viability). Interestingly, the addition 
of the 3,4-dimethoxybenzoyl group demonstrated an increase the compounds’ viability (93.7-100% 
cell viability), and demonstrated superior viability to control ebselen as well.  
 
Figure 4.14: Chemical structures of top PTZ and PSZ with good cell viability 
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Chapter 5: Molecular Docking Studies 
5.1 Introduction 
 This chapter describes the investigation of the binding interactions of promising PTZ and 
PSZ derivatives with human AChE and BuChE enzymes. The x-ray coordinates of 
cholinesterase enzymes were obtained from protein data bank (pdb ID: 4EY7 and 1POI, 
respectively), PTZ and PSZ ligands were built using computational software and docked 
enzyme-ligand complex were ranked using in-built scoring function to identify key interactions 
responsible for cholinesterase inhibition. In addition, the ability of some PTZ and PSZs to 
prevent amyloid aggregation was investigated by docking studies using an amyloid dimer 
assembly as a model (pdb ID: 2LMN).   
5.2 Principle 
Two methods are employed in the molecular modeling studies of the PTZ’s and PSZ’s; 
LibDock and CDocker both of which are used for molecular docking The LibDock protocol was 
developed by Diller and Merz.
127 
This method employs the use of protein site features referred to 
as HotSpots. HotSpots are classified into two types: polar and apolar or nonpolar. The LibDock 
method matches each specified ligand with the characterized receptor to generate different poses 
that are ranked based on the type of contact observed (polar/apolar) and ligand-receptor complex 
energy.  
CDocker is a refined docking protocol developed by Wu et al.
128
 Unlike Libdock, 
CDocker employs a grid-based molecular docking method that utilizes CHARMm. While the 
receptor is held rigid, the ligands docked are allowed to be flexible during the docking process. 
Through iterative steps the ligand poses are then optimized by grid-based simulated annealing to 
generate the top hits. The ligand poses obtained are ranked based on polar and nonpolar contacts 
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as well as ligand-receptor complex energy.  The LibDock protocol is useful to conduct rapid 
screening of compound libraries to determine potential binding modes with the target receptor 
whereas CDocker provides refined models to assist SAR optimization. 
Both LibDock and CDocker programs were used to determine the potential binding 
modes and interactions of select PTZ and PSZs with human AChE, BuChE and Aβ-dimer 
assembly. Discovery Studio Structure-Based-Design software package from BIOVIA/Accelrys 
Inc. was used. The results were validated by conducting molecular docking studies of known 
cholinesterase inhibitor tacrine by comparing with its solved crystal structure. Figure 5.1 gives a 
summary chart on the application of molecular docking in conjunction with compound library 
synthesis and biological evaluation. 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1: Schematics of molecular docking in conjunction with experimental methods 
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5.3 Results and Discussion 
5.3.1 Molecular docking of PTZ derivatives with ChE’s 
Figure 5.2: Docking of 10-H-phenothiazine (5) in the active site of hAChE (A) and hBuChE (B). 
Hydrogen atoms are not shown for clarity. Red: catalytic triad, Green: cationic site, Blue: PAS.  
The binding mode of 5 in hAChE (pdb ID: 4EY7) (Figure 5.2) demonstrates that its 
tricyclic core was sandwiched between the catalytic triad and cationic binding site with multiple 
hydrophobic pi-pi stacked interactions with Trp86 (distances ≈ 4.05 – 4.92 Å). A similar docking 
study of 5 within the hBuChE (pdb ID: 1P0I) active site shows that the tricyclic core was in a  
planar geometry closer to the cationic site of Trp82, with all three rings participating in multiple 
pi-pi stacked interactions (distances ≈ 3.60 – 5.39 Å) as shown in Figure 5.2. The closer 
proximity to the cationic site might account for its superior BuChE inhibition (AChE IC50 = 7.37 
µM, BuChE IC50 = 5.80 µM). 
A B 
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Figure 5.3: Docking of 1-(2-chloro-10H-phenothiazin-10-yl)-2-phenylethanone (7h) in the active 
site of hAChE (A) and hBuChE (B). Hydrogen atoms are not shown for clarity. Red: catalytic 
triad, Green: cationic site, Blue: PAS.  
The binding mode of 7h in hAChE (pdb ID: 4EY7) (Figure 5.3) shows that its tricyclic 
core was oriented across the cationic binding site with multiple hydrophobic pi-pi stacked 
interactions with Trp86 (distances ≈ 4.54 – 5.01 Å). One of the phenyl rings of the tricyclic core 
was able to interact with His447 through a pi-pi stacked interaction (distance ≈ 4.94 Å). It was 
also interesting to note that the N-10 phenylacetyl group was in close proximity to the Trp286 
which is part of the PAS (distance ≈ 3.87 Å).  Looking at its binding to hBuChE (pdb ID: 1P0I), 
the tricyclic core was closer to the cationic site of Trp82, and was more equidistant between both 
the cationic site and the catalytic triad. Key pi-pi stacked interactions are seen with Trp82 
(distances ≈ 4.08 – 4.67 Å), but its proximity to His447 also allowed for a favorable pi-pi T-
shaped interaction (distance ≈ 5.00 Å), hence providing better BuChE inhibition over AChE 
(AChE IC50 = 7.51 µM, BuChE IC50 = 3.64 µM). 
A B 
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Figure 5.4: Docking of 2-chloro-10H-phenothiazin-10-yl (4-methoxyphenyl)methanone (7j) in 
the active site of hAChE (A) and hBuChE (B). Hydrogen atoms are not shown for clarity. Red: 
catalytic triad, Green: cationic site, Blue: PAS.  
The binding mode of 7j in hAChE (pdb ID: 4EY7) (Figure 5.4) demonstrates that its 
tricyclic core was completely shifted away from cationic binding site at a perpendicular angle 
where it stretched upwards reaching towards the PAS compared to both 5 and 7h (Figures 5.2 
and 5.3). 7j had its chlorine participating in multiple hydrophobic pi-halogen interactions with 
Trp86 (distances ≈ 4.54 – 5.01 Å). The bottom portion of the tricyclic core allowed for a pi-pi T-
shaped interaction (distance ≈ 5.09 Å) with Trp86, while the upper portion was oriented closer to 
the Trp286 of PAS (distance ≈ 5.59 Å). The key interaction of 7j was with its N-10 4-
methoxybenzoyl substituent, where the 4-methoxy formed H-bonding with Ser203 (distance ≈ 
2.89 Å); the catalytic site which may account for its better AChE inhibition compared to both 5 
and 7h (AChE IC50 = 5.89 (7j) vs 7.37 and 7.51 µM respectively). Its binding mode towards 
hBuChE (pdb ID: 1P0I) shows that the tricyclic core adopted a planar conformation while 
A B 
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interacting with Trp82, and was equidistant from both the cationic site and the catalytic triad 
(Figure 5.4). Key pi-pi stacked interactions were seen with Trp82 (distances ≈ 4.36 – 5.30 Å). 
An interesting note was that the 4-methoxybenzoyl group was oriented away from the catalytic 
triad, but was in close proximity to Trp82 with the carbonyl oxygen participating in H-bonding 
interaction (distance ≈ 2.99 Å), whereas the phenyl ring underwent pi-pi stacked interaction 
(distance ≈ 5.58 Å). Thus, while the tricyclic core was not in an ideal position towards the 
cationic sites of both AChE and BuChE, the N-10 4-methoxybenzoyl groups made up for lost 
interactions by providing key contacts between the catalytic and cationic sites to afford a dual 
ChE inhibition profile (AChE IC50 = 5.89 µM, BuChE IC50 = 5.35 µM). 
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5.3.2 Molecular docking of PSZ derivatives with ChE’s 
 
Figure 5.5: Docking of 10-H-phenoselenazine (13) in the active site of hAChE (A) and hBuChE 
(B). Hydrogen atoms are not shown for clarity. Red: catalytic triad, Green: cationic site, Blue: 
PAS.  
The binding mode of 13 in hAChE (pdb ID: 4EY7) (Figure 5.5) demonstrates that its 
tricyclic core was closer to the cationic binding site than the catalytic triad and underwent 
hydrophobic pi-pi stacked interactions with Trp86 (distances ≈ 4.09 – 4.50 Å). Interestingly, the 
PSZ template exhibited a flipped conformation unlike 5 and the selenium moiety was away from 
His447. Its binding mode to hBuChE (pdb ID: 1P0I), showed that the tricyclic core was flipped 
back with the selenium moiety facing His447. The tricyclic core able to participate in multiple 
pi-pi stacked interactions with Trp82 (distances ≈ 4.00 – 5.55 Å). that accounts for its better  
BuChE inhibition (AChE IC50 = 5.63 µM, BuChE IC50 = 2.96 µM). 
A B 
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Figure 5.6: Docking of 2-chloro-10H-phenoselenazin-10-yl(phenyl)methanone (15g) in the 
active site of hAChE (A) and hBuChE (B). Hydrogen atoms are not shown for clarity. Red: 
catalytic triad, Green: cationic site, Blue: PAS.  
The binding mode of 15g in hAChE (pdb ID: 4EY7) (Figure 5.6) demonstrates that its 
tricyclic core was oriented away from both the catalytic triad and the cationic site. It is 
interesting to note that the N-10 benzoyl group was interacting with His447 through a pi-pi T-
shaped hydrophobic interaction (distance ≈ 4.83 Å). Its binding to hBuChE (pdb ID: 1P0I), 
shows that the N-10 benzoyl group underwent a pi-pi T-shaped interaction with His447 (distance 
≈ 4.35 Å). The carbonyl oxygen of the N-10 benzoyl group also formed a H-bond with Ser198 
(distance ≈ 3.10 Å). This showed that AChE and BuChE activity is not only dictated by the 
cationic site of Trp86 or Trp82 respectively, but that the catalytic triad plays a key role as well 
(AChE IC50 = 6.04 µM, BuChE IC50 = 3.88 µM). 
A B 
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Figure 5.7: Docking of 2-chloro-10H-phenoselenazin-10-yl(4-methoxyphenyl)methanone (15j) 
in the active site of hAChE (A) and hBuChE (B). Hydrogen atoms are not shown for clarity. Red: 
catalytic triad, Green: cationic site, Blue: PAS.  
The binding mode of 15j in hAChE (pdb ID: 4EY7) (Figure 5.7) demonstrates that its 
tricyclic core was closer to the cationic binding site than the catalytic triad and underwent 
hydrophobic pi-pi stacked interactions with Trp86 (distances ≈ 4.17 – 5.02 Å). The tricyclic ring 
with the selenium moiety of 15j, exhibited a similar conformation as 13, whereas the N-10 4-
methoxybenzoyl group was oriented away from the catalytic site. With hBuChE (pdb ID: 1P0I), 
15j exhibited an almost identical orientation like 15g, with its tricyclic core oriented away from 
both the catalytic site and the catalytic triad (Figure 5.7). The N-10 4-methoxybenzoyl group 
underwent a pi-pi T-shaped interaction with His438 (distance ≈ 4.31 Å). Furthermore, the 
addition of the 4-methoxy group underwent hydrophobic contacts with Trp82 (distance ≈ 3.74 Å). 
The carbonyl oxygen of the 4-methoxybenzoyl group formed H-bonding with Ser198 (distance ≈ 
A B 
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3.11 Å). These observations account for its dual ChE inhibition (AChE IC50 = 5.79 µM, BuChE 
IC50 = 4.91 µM). 
5.3.3 ChE Comparisons 
 
Figure 5.8: Comparison of binding modes 10-H-phenothiazine (5, yellow) and 10-H-
phenoselenazine (13, purple) in the active site of hAChE (A) and hBuChE (B). Hydrogen atoms 
are not shown for clarity. Red: catalytic triad, Green: cationic site, Blue: PAS.  
The binding modes of both 5 and 13 in hAChE (pdb ID: 4EY7) showed quite similar 
overlap in their distances both from the cationic site and the catalytic triad (Figure 5.8), although 
the PSZ 13 exhibited better AChE inhibition (AChE IC50 = 7.37 and 5.63 µM respectively). 
Similarly, in the hBuChE (pdb ID: 1P0I) active site, both compounds showed better angle of 
contact with the cationic site of Trp82, hence their increased potency (BuChE IC50 = 5.35 and 
2.96 µM respectively). 
A B 
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Figure 5.9: Comparison of binding modes of 2-chloro-10H-phenothiazin-10-yl (4-
methoxyphenyl)methanone (7j, yellow) and 2-chloro-10H-phenoselenazin-10-yl (4-
methoxyphenyl)methanone (15j, purple)  in the active site of hAChE (A) and hBuChE (B). 
Hydrogen atoms are not shown for clarity. Red: catalytic triad, Green: cationic site, Blue: PAS  
The binding modes of both 7j and 15j in hAChE (pdb ID: 4EY7) showed different poses 
in their orientations (Figure 5.9). Despite of this, their inhibition values are similar (AChE IC50 
= 5.89 and 5.79 µM respectively). In 7j the 4-methoxybenzoyl group interacted with both Trp86 
and Ser203, while in 15j the tricyclic ring was closer to Trp86 and His447. Similarly, looking at 
the hBuChE (pdb ID: 1P0I) active site, both compounds again showed drastic differences in their 
poses but similar inhibition values (BuChE IC50 = 5.80 and 4.91 µM respectively). While 7j 
utilized a combination of both the tricyclic core and the 4-methoxybenzoyl group to block the 
cationic Trp82, 15j relied almost exclusively on the 4-methoxybenzoyl group to interact with the 
A B 
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catalytic triad’s Ser298 and His438. These results suggest that multiple interactions with both the 
catalytic triad and cationic site play a significant role in ChE inhibition. 
 
Figure 5.10: Comparison of binding modes of 10H-phenoselenazin-10-yl (phenyl)methanone 
(15a, purple) and 2-chloro-10H-phenoselenazin-10-yl (phenyl)methanone (15g) in the active site 
of hAChE (A) and hBuChE (B). Hydrogen atoms are not shown for clarity. Red: catalytic triad, 
Green: cationic site, Blue: PAS 
The binding modes of both 15a and 15g in hAChE (pdb ID: 4EY7) show different 
orientations, but similar distances from both the cationic site and the catalytic triad (Figure 5.10). 
Accordingly, their AChE inhibition values were also similar (AChE IC50 = 5.43 and 6.04 µM 
respectively). In the hBuChE (pdb ID: 1P0I) active site, 15a had its tricyclic core oriented away 
from the cationic site, and had its benzoyl group sticking away from the cationic site giving it 
poor BuChE inhibition (BuChE IC50 = 22.75 µM). In compound 15g, its tricyclic core was also 
A B 
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oriented away, but its benzoyl group was oriented between both the catalytic triad and the 
cationic site and underwent two key interactions with the Ser198 and His438, giving it superior 
BuChE potency over its unchlorinated analog (BuChE IC50 = 3.88 µM). 
5.3.4 Molecular docking of PTZ derivatives with amyloid dimer 
 
Figure 5.11: Docking of 10-H-phenothiazine (5, A) and 2-chloro-10-H-phenothiazine (6, B) in 
the amyloid beta dimer model. Hydrogen atoms are not shown for clarity. Red: Chain A, Blue: 
Chain B 
The binding mode of 5 and 6 was investigated in the Aβ dimer model (pdb ID: 2LMN). 
The binding mode of 5 showed that its tricyclic core was in a perfect position to provide 
hydrophobic pi-pi stacked interactions with Phe19 of chain A (distances ≈ 3.65 – 4.65 Å) as 
shown in Figure 5.11. One of the phenyl rings of the tricyclic core was also able to network with 
Phe20 of chain A through pi-pi T-shaped interaction (distance ≈ 5.69 Å). The nitrogen was H-
bonded to the Val18 backbone oxygen (distance ≈ 1.91 Å). The binding mode of 6 showed 
A B 
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similar features in its interaction with the amyloid dimer. The tricyclic core was slightly further 
away compared to 5, but was still able to interact with Phe19 and Phe20 of chain A through pi-pi 
stacking (distances ≈ 4.75 – 5.22 Å). The nitrogen was too far for H-bonding, but instead the 
added chlorine provided pi-halogen interactions with Phe19 (distance ≈ 4.95 Å) and Leu17 
(distance ≈ 4.56 Å) respectively. Both 5 and 6 docked in similar positions to the amyloid dimer 
in the hydrophobic KLVFFA region which known to be the nucleation site of Aβ-aggregation 
(Figure 5.11). Specifically, strong interactions with both Phe19 and Phe20 of chain A were seen. 
The added proximity and pi-pi T-shaped interaction of compound 5 might contribute to its better 
anti-aggregation activity compared to the C-2 chloro compound 6. 
5.3.5 Molecular docking of PSZ derivatives with amyloid dimer 
Figure 5.12: Docking of 10-H-phenoselenazine (13, A) and 2-chloro-10-H-phenoselenazine (14, 
B) in the amyloid beta dimer model. Hydrogen atoms are not shown for clarity. Red: Chain A, 
Blue: Chain B 
A B 
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The binding mode of 13 and 14 was investigated in the Aβ dimer model (pdb ID: 2LMN). 
The binding mode of 13 showed (Figure 5.12) that its tricyclic core was oriented in a 
perpendicular fashion relative to Phe19 of chain A, leading to a pi-pi T-shaped interaction 
(distance ≈ 5.62 Å). The tricyclic core was also able to network with Phe20 of chain A through 
pi-pi stacked interaction (distance ≈ 4.58 Å). It was also interacting with amino acids that form 
the turn region of the Aβ dimer, allowing a pi-alkyl interaction with Ala21 of chain A (distance ≈ 
4.18 Å). The binding mode of 14 showed very similar features as compound 13. The tricyclic 
core underwent pi-pi T-shaped and pi-pi stacked interactions (distances ≈ 5.71 and 4.44 Å 
respectively) with Phe19 and Phe20. The added C-2 chlorine provided an additional pi-alkyl 
interaction with Ala21 (distance ≈ 3.80 and 4.37 Å). Both 13 and 14 docked in very similar 
positions to the Aβ dimer in the hydrophobic KLVFFA region where aggregation is known to 
take place. Specifically, strong interactions with both Phe19, Phe20 and Ala21 of chain A were 
seen. As a result, both 13 and 14 exhibited almost identical anti-aggregation inhibition. 
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5.3.6 Amyloid Comparisons 
 
 
 
 
 
 
 
 
 
 
Figure 5.13: Comparison of binding modes of 10-H-phenothiazine (5, yellow) and 10-H-
phenoselenazine (13, purple) in the Aβ dimer model. Hydrogen atoms are not shown for clarity. 
Red: Chain A, Blue: Chain B 
Both 5 and 13 exhibited different binding modes to the Aβ dimer model (pdb ID: 2LMN) 
(Figure 5.13). However, both showed good anti-aggregation activity towards the self-induced 
Aβ1-42 with comparable potency relative to the reference agent orange G. Both bound in the 
hydrophobic KLVFFA region of the Aβ dimer, which highlights the importance of the proximity 
to that region.  
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5.4 Conclusions  
Both PTZ’s and PSZ’s exhibit different binding modes within the active sites of both AChE and 
BuChE enzymes.  The AChE docking results gave similar poses across all compounds, evident 
in the relatively low range of inhibitory values across all compounds (AChE IC50 = 4.63 – 9.97 
µM). Significant differences occurred in their ability to inhibit BuChE enzymes. For example, 
compound 7h was most BuChE inhibitor in the PTZ series (BuChE IC50 = 3.64 µM). Among the 
PSZ’s compound 13 showed the importance of proximity towards the cationic binding site as 
well which led to potent  BuChE inhibition (IC50 = 2.96 µM). These studies indicate that the 
cholinesterase inhibition relies on the proximity of either PTZ and PSZ compounds towards the 
cationic site of Trp (86 or 82) and or the catalytic triad (Ser, His, Glu).  
In the Aβ dimer model, nonacylated PTZ and PSZs exhibited good anti-aggregation 
properties suggesting that a either a sulfur or selenium based fused tricyclics are a useful 
template to design anti-amyliid agents. It also shows that compounds that interact with the 
hydrophobic KLVFFA region exhibit good anti-aggregation properties. Interestingly, the PTZ 
and PSZ compounds evaluated interacted with chain A exclusively in the modeling. Key 
interactions were seen with both the phenylalanine residues at 19 and 20 of chain A, indicating 
the importance of nonpolar interactions and anti-aggregation properties.  
The molecular docking studies showed that the tricyclic ring templates PTZ and PSZ’s 
have the ability to bind to both AChE and BuChE. Their inhibitory potency can be modulated by 
steric and electronic factors. Furthermore, nonacylated PTZ and PSZ’s exhibit good anti-
aggregation properties suggesting that these small molecules can exhibit dual ChE and anti-
amyloid properties and their potential development as anti-AD agents. 
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Chapter 6: Conclusion and Future Directions 
6.1 Conclusion 
 Over the course of this research project a compound library of 26 PTZ and PSZ 
derivatives were designed, chemically synthesized, and biologically evaluated for their AChE, 
BuChE, anti-amyloid aggregation, antioxidant and cell viability activity.  
 PTZ and PSZ design were developed through a combination of reviewing of past 
literature to encompass the most optimal functional groups to help create a multi-target 
compound library, and utilizing preliminary computational modeling studies to further assess 
compound potential. The compound library synthesized through organic chemistry utilized 
different methods and approaches to give yields ranging from 25 – 95%. Biological evaluations 
were accomplished through previously developed protocols optimized for the purpose of this 
project. After biological profiles were established for the ChE and anti-amyloid aggregation 
assays, computational modeling was re-examined as a tool to view specific binding patterns to 
validate SAR data found. A summary of the drug properties for PTZ (5, 6, 7a-l) and PSZ (13, 14, 
15a-l) are outlined below: 
 
Molecular Weights (MW): 199.27 – 444.77 Da  
Partition Coefficient (ClogP): 3.56 – 6.96 
AChE Inhibition (IC50): 4.63 – 9.97 µM 
BuChE Inhibition (IC50): 3.00 – 110.52 µM 
Anti-Amyloid Aggregation (% inhibition at 25 µM): 5.9 – 61.9% 
Antioxidant Capacity (% Inhibition at 50 µM): 38.3 – 92.1% 
Neuroblastoma Cell Viability (at 50 µM): 43.0 – 100% 
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The ChE profiles of the 26 synthesized novel tricyclics showed moderate inhibition. 
(Table 4.1 and 4.2) In general, the derivates exhibited better AChE inhibition compared to 
BuChE. The introduction of N-acyl groups increased AChE potency but not to a great extent. 
The most potent AChE inhibitor was 15d ((4-methoxyphenyl)-10H-phenoselenazin-10-
ylmethanone; AChE IC50 = 4.63 µM). The most potent BuChE inhibitor was 13 (10H-
phenoselenazine; BuChE IC50 = 3.00 µM), which had better BuChE inhibition compared to 
donepezil and galantamine, but not as potent as tacrine (BuChE IC50 = 0.04 µM). The 2-chloro 
derivates greatly improved BuChE potency compared to their unchlorinated analogs, making 
them suitable dual cholinesterase templates. Overall the best dual cholinesterase derivative was 
seen for 15j (2-chloro-10H-phenoselenazin-10-yl(4-methoxyphenyl)methanone; AChE IC50 = 
5.79 µM, BuChE IC50 = 4.91 µM).  
 Select derivatives were screened for their amyloid aggregation inhibition towards self-
induced Aβ1-42 (Table 4.3 and 4.4). The unsubstituted derivatives showed that they were able to 
decrease Aβ1-42 fibril formation, affecting both the growth and saturation phases (% inhibition at 
25 µM: 45.0 – 61.9%). The N-acylation was detrimental to aggregation activity as there was up 
to 10-fold decrease seen in their anti-aggregation activity (% inhibition at 25 µM: 5.9 – 11.1%). 
The most potent anti-amyloid aggregation inhibitor was 5 (10H-phenothiazine; % inhibition at 
25 µM = 61.9%) which showed greater potency than orange G. 
 The same derivatives were also screened for their antioxidant properties towards radical 
scavenging (Table 4.5 and 4.6). The derivatives showed moderate to good antioxidant capacities 
(% inhibition at 50 µM: 38.3 – 92.1%). Showing a similar trend as the amyloid aggregation assay, 
the unsubstituted derivatives showed that they were potent antioxidant radical scavengers (% 
inhibition at 50 µM: 73.2 – 92.1%) as they exhibited comparable potency to trolox (% inhibition 
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at 50 µM: 99.2%). The N-acylation again affected their activity and there was approximately 2-
fold decrease in their antioxidant activity. 
 SHSY-5Y neuroblastoma cell viability was also assessed in the presence of select test 
compounds. Generally they showed moderate to good values (% cell viability at 50 µM: 43.0 – 
100%). The addition of N-acyl substituents to these compounds increased their cell viability. 
This effect was more pronounced in the PSZ series, with compound 15l (2-chloro-10H-
phenothiazin-10-yl(3,4-methoxyphenyl)methanone; % cell viability at 50 µM: 100%)  showing 
the best viability. 
 The combined SAR data for the novel tricyclics synthesized show that they serve as 
suitable templates as dual cholinesterase inhibitors with mutli-target abilities. 
 
6.2 Future directions 
 Based on the current SAR and biological profiles of PTZ and PSZ derivatives, future 
studies pertaining to this research include the expansion of this novel class of tricyclics to 
enhance ChE profiles, anti-amyloid aggregation and antioxidant properties. As seen in the ChE 
SAR, the addition of the chlorine at the C-2 position provides increased BuChE potency, thus the 
inclusion of other suitable electron withdrawing groups at the C-2 or C-3 position may lead to 
enhanced ChE SAR. Another interesting idea is to incorporate a heterocyclic into the either the 
PTZ or PSZ core, rather than have substituents at the C-2 or C-3 position. Starting from 3 or 4-
aminopyridine’s, following the synthetic protocols of Schemes 3.5 – 3.8 to afford a completely 
new library of novel tricyclics (Figure 6.1). 
 Replacing the benzoyl group with heterocyclics such as pyridines or smaller cyclic 
groups such as furans may help in the anchoring to the PAS of AChE. 
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 For both the anti-amyloid aggregation and antioxidant assays the N-acyl derivatives 
proved to be detrimental, thus the exploration of different C-2 and C-3 derivatives may provide 
enhanced results.  
 The next step in biological evaluations would also be the inclusion of the AChE-induced 
amyloid aggregation assay. As mentioned, the PAS of AChE is known to act as a nucleation site 
for aggregation to occur. Through the use of computational modeling, N-acylated compounds 
can be screened for their relative proximity to the PAS, where the best compounds can be chosen 
and synthesized. This inclusion of the AChE-induced aggregation assay may help in identifying 
novel PTZ and PSZ derivatives.  
 
 
Figure 6.1: Future development of novel PTZ and PSZ derivatives 
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Chapter 7: Experimental 
7.1 Chemistry 
All solvents and reagents used were purchased from various industrial vendors (Acros 
Organics®, Sigma Aldrich®, and Alfa Aesar®) with minimum purity of 95% and used without 
further purification.  Melting points were determined using a Fisher-Johns apparatus and are 
uncorrected. 
1
H-NMR and 
13
C-NMR spectra were performed on a Bruker Avance (300 and 75 
MHz respectively) series spectrometer using CDCl3 or DMSO-d6 as the solvent. Coupling 
constants (J-values) were recorded in hertz (Hz) and the following abbreviations were used to 
represent the multiplicity of NMR signals: s = singlet, d = doublet, t = triplet, m = multiplet, br = 
broad. Carbon multiplicities (C, CH, CH2, CH3) were assigned by DEPT 90/135 experiments. 
High-resolution mass spectrometry analysis was done through positive ion electrospray 
ionization (ESI) using a Thermo Scientific Q-Exactive mass spectrometer. The mass 
spectrometry data for PSZ and PSZ derivatives are reported based on the most stable selenium 
isotope (
80
Se). Crude product purification was done using flash chromatography with Merck 
230-400 mesh silica gel 60. Combustion analysis was carried out by Midwest Microlab, LLC 
(Indianapolis, IN) on select compounds with the % C, H, N within ± 0.4% of theoretical values. 
All compounds were tested for purity by both HPLC analysis on an Agilent HPLC system and 
through thin-layer chromatography (TLC) showing up as a single spot, performed on Merck 
60F254 silica gel plates (0.2 mm) using three different solvent systems (5:1 EtOAc:MeOH, 
DCM, 5:1 hexane:EtOAc) to confirm > 95% purity.  
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7.1.1 General method for the preparation of PTZ derivatives (7a-l) 
To a mixture of phenothiazine (5) or 2-chlorophenothiazine (6) (0.40 g, 2.01 mmol) in 7 mL of 
anhydrous toluene at rt, the desired acyl chloride (R = phenyl, benzyl, ethylphenyl, 3-
methoxyphenyl, 4-methoxyphenyl or 3,4-dimethoxyphenyl) was added (1.5 equiv). The reaction 
mixture was refluxed overnight at 110 °C and was monitored by TLC. Upon completion, the 
excess toluene was evaporated in vacuo. The crude product was purified via flash 
chromatography using DCM as the solvent. Final compound yields ranged from 70 - 95%. 
10H-Phenothiazine (5): Yellow solid. 
1
H NMR (DMSO-d6, 300 MHz) δ 8.57 (s, 1H), 6.98 (t, J 
= 7.5 Hz, 2H), 6.91 (d, J = 7.2 Hz, 2H), 6.74 (t, J = 7.5 Hz, 2H), 6.68 (d, J = 7.8 Hz, 2H).
 13
C 
NMR (DMSO-d6, 75 MHz) δ 114.5 (CH), 116.2 (C), 121.7 (CH), 126.2 (CH), 127.5 (CH), 142.0 
(C). 
2-Chloro-10H-phenothiazine (6): Yellow powder. 
1
H NMR (DMSO-d6, 300 MHz) δ 8.70 (s, 
1H), 6.97 (t, J = 7.1 Hz, 1H), 6.88 (d, J = 8.1 Hz, 2H), 6.72 - 6.77 (m, 2H), 6.61 - 6.66 (m, 2H). 
10H-Phenothiazin-10-yl (phenyl)methanone (7a): White solid (80%). mp: 175-177°C. 
1
H 
NMR (DMSO-d6, 300 MHz) δ 7.55 - 7.63 (m, 2H), 7.41 - 7.49 (m, 2H), 7.32 - 7.41 (m, 1H), 
7.19 - 7.32 (m, 8H).  
1-(10H-Phenothiazin-10-yl)-2-phenylethanone (7b): Yellow solid (94%). mp = 153-155°C. 
1
H 
NMR (CDCl3, 300 MHz) δ 7.54 (d, J = 7.7 Hz, 2H), 7.31 - 7.41 (m, 5H), 7.18 - 7.24 (m, 4H), 
7.06 - 7.11(m, 2H), 3.83 (s, 2H). 
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1-(10H-Phenothiazin-10-yl)-3-phenylpropan-1-one (7c): Yellow solid (77%). mp = 98-
100°C.
1
H NMR (DMSO-d6, 300 MHz) δ 7.57 (d, J = 7.8 Hz, 2H), 7.52 (dd, J = 7.7 Hz, 1.3, 2H), 
7.35 (td, J = 7.7, 1.5 Hz, 2H), 7.23 - 7.31 (m, 2H), 7.00 - 7.23 (m, 5H), 2.63 - 2.85 (br s, 4H). 
 (4-Methoxyphenyl)-10H-phenothiazin-10-ylmethanone (7d): White crystalline solid (71%). 
mp = 170-173°C.
  1
H NMR (DMSO-d6, 300 MHz) δ 7.50 - 7.58 (m, 2H), 7.39 - 7.46 (m, 2H), 
7.18 - 7.25 (m, 6H), 6.78 (d, J = 8.9 Hz, 2H), 3.69 (s, 3H); HRMS (ESI) m/z calcd for 
C20H16NO2S ([M + H]
+
); 334.0902. Found 334.0895. 
(3-Methoxyphenyl)-10H-phenothiazin-10-ylmethanone (7e): White crystalline solid (83%).
 
mp = 155-157°C. 
1
H NMR (DMSO-d6, 300 MHz) δ 7.51 - 7.58 (m, 2H), 7.38 - 7.46 (m, 2H), 
7.18 - 7.26 (m, 4H), 7.14 (t, J = 7.8 Hz, 1H), 6.88 (dd, J = 8.0, 2.2 Hz, 1H), 6.77 - 6.84 (m, 2H), 
3.60 (s, 3H); HRMS (ESI) m/z calcd for C20H16NO2S ([M + H]
+
); 334.0902. Found 334.0895.  
(3,4-Dimethoxyphenyl)-10H-phenothiazin-10-ylmethanone (7f): Pale yellow solid (70%). mp 
= 176-178°C.
 1
H NMR (DMSO-d6, 300 MHz) δ 7.51 - 7.58 (m, 2H), 7.39 - 7.46 (m, 2H), 7.19 - 
7.26 (m, 4H), 6.86 - 6.91 (m, 1H), 6.76 - 6.84 (m, 2H), 3.69 (s, 3H), 3.50 (s, 3H); 
13
C NMR 
(DMSO-d6, 75 MHz) δ 55.1 (CH3), 55.5 (CH3), 110.7 (CH), 112.0 (CH), 121.2 (CH), 126.6 (CH), 
126.8 (CH), 127.2 (CH), 127.7 (CH), 131.3 (C), 139.4 (C), 147.7 (C), 150.5 (C), 167.4 (C). 
HRMS (ESI) m/z calcd for C21H18NO3S ([M + H]
+
); 364.1007. Found 364.1003. 
2-Chloro-10H-phenothiazin-10-yl(phenyl)methanone (7g): Green solid mp: 157-160°C
 1
H 
NMR (DMSO-d6, 300 MHz) δ 7.64 (d, J = 7.2 Hz, 2H), 7.48 (d, J = 7.7 Hz, 2H), 7.38 (td, J = 
7.6 Hz, 3, 2H), 7.23 - 7.31 (m, 2H), 7.13 - 7.18 (m, 2H), 6.90 - 6.97 (m, 2H). 
1-(2-Chloro-10H-phenothiazin-10-yl)-2-phenylethanone (7h): Yellow solid (94%). mp = 90-
92°C. 
1
H NMR (DMSO-d6, 300 MHz) δ 7.74 (s, 1H), 7.65 (d, J = 7.81, 2H), 7.45 - 7.52 (m, 2H), 
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7.22 - 7.45 (m, 3H), 7.12 - 7.21 (m, 3H), 6.90 - 6.98 (m, 2H), 3.82 (s, 2H); HRMS (ESI) m/z 
calcd for C20H15ClNOS ([M + H]
+
); 352.0563. Found 352.0558. 
1-(2-Chloro-10H-phenothiazin-10-yl)-3-phenylpropan-1-one (7i): Yellow oil (95%). 
1
H NMR 
(DMSO-d6, 300 MHz) δ 7.67 (s, 1H), 7.49 - 7.61 (m, 3H), 7.33 - 7.41 (m, 2H), 7.25 - 7.33 (m, 
1H), 7.14 – 7.22 (m, 2H), 7.11 (d, J = 7.0 Hz, 1H), 7.00 - 7.08 (m, 2H), 2.65 - 2.83 (br s, 4H); 
HRMS (ESI) m/z calcd for C21H17ClNOS ([M + H]
+
); 366.0719. Found 366.0717. 
2-Chloro-10H-phenothiazin-10-yl(4-methoxyphenyl)methanone (7j): Yellow solid (94%). 
mp = 153-155°C. 
1
H NMR (DMSO-d6, 300 MHz) δ 7.68 (s, 1H), 7.51 - 7.60 (m, 2H), 7.30 - 7.36 
(m, 1H), 7.14 - 7.30 (m, 5H), 6.81 (d, J = 8.7 Hz, 2H), 3.70 (s, 3H); HRMS (ESI) m/z calcd for 
C20H15ClNO2S ([M + H]
+
); 368.0512. Found 368.0510. 
2-Chloro-10H-phenothiazin-10-yl(3-methoxyphenyl)methanone (7k):
 
White solid (92%). mp 
= 140-142°C. 
1
H NMR (DMSO-d6, 300 MHz) δ 7.64 (s, 1H), 7.56 (t, J = 8.6 Hz, 2H), 7.26 - 7.37 
(m, 2H), 7.13 - 7.26 (m, 3H), 6.91 (d, J = 8.3 Hz, 1H), 6.77 - 6.86 (m, 2H), 3.62 (s, 3H); HRMS 
(ESI) m/z calcd for C20H15ClNO2S ([M + H]
+
); 368.0512. Found 368.0509. 
2-Chloro-10H-phenothiazin-10-yl(3,4-methoxyphenyl)methanone (7l): Yellow solid (73%). 
mp = 155-158°C. 
1
H NMR (DMSO-d6, 300 MHz) δ 7.69 (s, 1H), 7.52 - 7.60 (m, 2H), 7.31 - 7.37 
(m, 1H), 7.15 - 7.29 (m, 3H), 6.77 - 6.92 (m, 3H), 3.70 (s, 3H), 3.51 (s, 3H); HRMS (ESI) m/z 
calcd for C21H17ClNO3S ([M + H]
+
); 398.0618. Found 398.0613. 
7.1.2 General method for the preparation of diphenylamines (11 and 12) 
 The diphenylamine derivatives were prepared by four methods highlighted by Schemes 
3.2 – 3.6. Copper (II) acetate was used as a catalyst in Schemes 3.2 – 3.4, which provided yields 
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of up to 30%. Schemes 3.5 and 3.6 highlight a two-step metal-free approach that gave superior 
yields of up to 50%. 
Method 1: To a mixture of phenylboronic acid (0.61g, 5.00 mmol) in 10 mL of H2O, aniline (8) 
or 3-chloroaniline (9) was added (3 equiv) with the copper(II)-β-cyclodextrin complex (0.05 
equiv). The reaction mixture was allowed to stir overnight at rt. Upon completion, the reaction 
mixture was diluted with 50 mL of water and extracted with 20 mL of DCM three times. The 
organic layer was combined and evaporated in vacuo and the crude product was purified via 
flash chromatography using DCM as a solvent. Final compound yields were in the range of 6 – 
10% (Scheme 3.2). 
Method 2: To a mixture of aniline (8) or 3-chloroaniline (9) (5.48 mmol) in 20 mL of EtOAC, 
phenylboronic acid (2 equiv), copper acetate (0.2 equiv), sodium bicarbonate (1 equiv) and 
benzoic acid (0.5 equiv) was added. The reaction mixture was allowed to stir overnight at rt. 
Upon completion, the excess EtOAC was evaporated and the crude residue was re-diluted with 
DCM. The organic layer washed with brine, separated and evaporated in vacuo. The crude 
product was purified via flash chromatography using DCM as a solvent. Final compound yields 
were in the range of 18 – 25% (Scheme 3.3). 
Method 3: To a mixture of aniline (8) or 3-chloroaniline (9) (5.48 mmol) in 20 mL of toluene, 
phenylboronic acid (2 equiv), copper acetate (0.1 equiv), 2,6-lutidine (1 equiv) and myrisstic 
acid (0.2 equiv) was added. The reaction mixture was allowed to stir overnight at 80°C. Upon 
completion, the excess toluene was evaporated and the crude residue was re-diluted with 2M 
HCl and the aqueous layer was extracted with DCM. The organic layer was separated and 
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evaporated in vacuo. The crude product was purified via flash chromatography using DCM as a 
solvent. Final compound yields were in the range of 32 – 38% (Scheme 3.4). 
Method 4: To a mixture of cyclohex-2-enone (1 mL, 10.33 mmol) in 50 mL of 1:1 THF:H2O, 
iodine (1.5 equiv), DMAP (1 equiv) and potassium carbonate (1.2 equiv) was added. The 
reaction mixture was allowed to stir at rt for 30 mins. Upon completion, the reaction mixture was 
diluted with EtOAc. The organic layer was washed with saturated sodium thiosulfate and 10% 
HCl. The organic layer was separated and evaporated in vacuo and the crude product was 
purified via flash chromatography using DCM as the solvent. Final compound yields were I nthe 
range of 40 - 70% (Scheme 3.5). 
Method 5: To a mixture of aniline (8) or 3-chloroaniline (9) (4.8 mmol) in 10 mL EtOH, α-
iodonated 2-cyclohex-2-enone (10, 1.2 equiv) and p-TsOH (0.2 equiv) was added. The reaction 
mixture was refluxed overnight at 75 °C. Upon completion, the reaction mixture was diluted 
with EtOAc. The organic layer was washed with 20% sodium bicarbonate and saturated brine 
solution. The organic layer was separated and evaporated in vacuo. The crude product was 
purified via flash chromatography using DCM as the solvent. Final compound yields were in the 
range of 40 – 50% (Scheme 3.6). 
2-Iodocyclohex-2-enone (10): Yellow solid (40-70%). mp = 49-50°C. 
1
H NMR (DMSO-d6, 300 
MHz) δ 7.78 (t, J = 4.4 Hz, 1H), 2.51 - 2.63 (m, 2H), 2.34 - 2.43 (m, 2H), 1.93 (quin, J = 6.3 Hz, 
2H). 
Diphenylamine (11): Yellow solid (40-50%). mp = 50-52°C. 
1
H NMR (DMSO-d6, 300 MHz) δ 
8.08 (s, 1H), 7.18 (t, J = 7.8 Hz, 4H), 7.02 (d, J = 8.1 Hz, 4H), 6.77 (t, J = 7.2 Hz, 2H) 
13
C NMR 
(DMSO-d6, 75 MHz) δ 116.7 (CH), 119.6 (CH), 129.1 (CH), 143.4 (C). 
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3-Chloro-N-phenylaniline (12): Brown oil (40-50%). 
1
H NMR (DMSO-d6, 300 MHz) δ 8.36 (s, 
1H), 7.22 - 7.30 (m, 2H), 7.19 (t, J = 8.2 Hz, 1H), 7.07 (d, J = 8.1 Hz, 2H), 6.93 - 7.01 (m, 2H), 
6.88 (t, J = 7.3 Hz, 1H), 6.78 (d, J = 8.1 Hz, 1H). 
7.1.3 General method for the preparation of PSZ’s (13 and 14) 
 The unsubstituted PSZ (13 and 14) were prepared by two different methods highlighted 
by Schemes 3.7 and 3.8. Scheme 3.7 utilized selenium monochloride as the selenium source and 
gave poor yields in the range of 5 – 10%. Scheme 3.8 shows an alternative approach that used a 
combination of selenium and selenium dioxide to help regenerate the selenium available in-situ, 
giving a slight improvement of yields up to 25%. 
Method 1: To a mixture of diphenylamine (11) or 4-chloro-N-phenylaniline (12) (6.00 mmol) in 
10 mL of DCM, selenium monochloride was added dropwise (1.5 equiv) at rt. Upon complete 
addition, the reaction mixture was refluxed for 5 hr. Upon completion, the reaction mixture was 
filtered through a DCM plug of celite. The excess organic layer was evaporated in vacuo and the 
crude product was purified via flash chromatography using 5:1 hexanes:EtOAc as the solvent. 
Final compounds yields were in the range of 5 – 10% (Scheme 3.7). 
Method 2: To a mixture of selenium (1.00 g, 12.79 mmol) in 5 mL of sulpholane, the appropriate 
diphenylamine (11 or 12) (2 equiv), selenium dioxide (1.20 equiv), and iodine (0.1 equiv) was 
added. The reaction mixture was sealed in a pressure vial and placed in at oil bath at 150 °C for 5 
hours. Upon completion, the RM was filtered through a DCM plug of celite. The crude product 
was evaporated in vacuo and purified by recrystallization using EtOH and then subsequently by 
flash chromatography using 5:1 hexanes:EtOAc as the solvent. Final compound yields were in 
the range of 20 – 25% (Scheme 3.8). 
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10H-Phenoselenazine (13): yellow solid (20%). mp: 195-197°C. 
1
H NMR (DMSO-d6, 300 
MHz) δ 8.56 (s, 1H), 6.95 - 7.10 (m, 4H), 6.68 – 6.78 (m, 4H); 13C NMR (DMSO-d6, 75 MHz) δ 
111.5 (C), 115.1 (CH), 122.1 (CH), 127.8 (CH), 128.8 (CH), 142.1 (CH). HRMS (ESI) m/z calcd 
for C12H10N
80
Se ([M + H]
+
); 247.9978. Found 246.9895. 
2-Chloro-10H-phenoselenazine (14): Yellow solid (26%) mp = 199-200°C. δ 8.74 (s, 1H), 6.97  
- 7.14 (m, 3H), 6.66 – 6.83 (m, 4H); HRMS (ESI) m/z calcd for C12H9ClN
80
Se ([M + H]
+
); 
281.9589. Found 280.9500. 
7.1.4 General method for the preparation of PSZ derivatives (15a-l) 
To a mixture of phenoselenazine or 2-chlorophenoselenazine (0.356 mmol) in 7 mL of 
anhydrous toluene, the desired acyl chloride (R = benzoyl, phenyl acetyl, hydrocinnamoyl, 3-
methoxy, 4-methoxy or 3,4-dimethoxy) was added (1.5 equiv). The reaction mixture was 
refluxed overnight at 110 °C. Upon completion, the excess toluene was evaporated in vacuo. The 
crude product was purified via flash chromatography using DCM as the solvent. Final compound 
yields ranged from 20 - 80%. 
10H-Phenoselenazin-10-yl(phenyl)methanone (15a): Yellow solid (87%). mp = 157-159°C. 
1
H NMR (DMSO-d6, 300 MHz) δ 7.65 - 7.73 (m, 2H), 7.39 - 7.45 (m, 2H), 7.13 - 7.26 (m, 9H); 
HRMS (ESI) m/z calcd for C19H14NO
80
Se ([M + H]
+
); 352.0241. Found 352.0235. 
1-(10H-Phenoselenazin-10-yl)-2-phenylethanone (15b): Yellow solid (91%). mp = 111-113°C. 
1
H NMR (DMSO-d6, 300 MHz) δ 7.66 (d, J = 7.6 Hz, 4H), 7.40 (t, J = 7.6 Hz, 2H), 7.22 - 7.30 
(m, 2H), 7.13 - 7.21 (m, 3H), 6.90 - 6.99 (m, 2H), 3.72 (s, 2H); HRMS (ESI) m/z calcd for 
C20H16NO
80
Se ([M + H]
+
); 366.0397. Found 366.0393. 
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1-(10H-Phenoselenazin-10-yl)-3-phenylpropan-1-one (15c): Yellow solid (87%). mp = 106-
109°C. 
1
H NMR (DMSO-d6, 300 MHz) δ 7.68 (d, J = 7.6 Hz, 2H), 7.57 (d, J = 7.8 Hz, 2H), 7.36 
(t, J = 7.5 Hz, 2H), 7.06 - 7.28 (m, 5H), 7.02 (d, J = 7.2 Hz, 2H), 2.73 (s, 2H), 2.61 (br s, 2H); 
HRMS (ESI) m/z calcd for C21H18NO
80
Se ([M + H]
+
); 380.0554. Found 380.0546. 
(4-Methoxyphenyl)-10H-phenoselenazin-10-ylmethanone (15d): White solid (79%). mp = 
184-186°C. 
1
H NMR (DMSO-d6, 300 MHz) δ 7.66 - 7.72 (m, 2H), 7.39 - 7.47 (d, J = 7.3 Hz, 
2H), 7.13 - 7.27 (m, 6H), 6.76 (d, J = 8.7 Hz, 2H), 3.68 (s, 3H); HRMS (ESI) m/z calcd for 
C20H16NO2
80
Se ([M + H]
+
); 382.0346. Found 382.0339. 
(3-Methoxyphenyl)-10H-phenoselenazin-10-ylmethanone (15e): White solid (84%). mp = 
157-159°C. 
1
H NMR (DMSO-d6, 300 MHz) δ 7.71 (dd, J = 7.1, 1.7 Hz, 2H), 7.44 (d, J = 7.5 Hz, 
2H), 7.09 - 7.29 (m, 5H), 6.77 - 6.92 (m, 3H), 3.60 (s, 3H); HRMS (ESI) m/z calcd for 
C20H16NO2
80
Se ([M + H]
+
); 382.0346. Found 382.0338. 
 (3,4-Dimethoxyphenyl)-10H-phenoselenazin-10-ylmethanone (15f):
 
Yellow solid (73%). mp 
=  185-187°C. 
1
H NMR (DMSO-d6, 300 MHz) δ 7.71 (d of d, J = 7.3, 1.7 Hz, 2H), 7.44 (d of d, 
J = 7.7 Hz, 1.4, 2H), 7.14 - 7.29 (m, 4H), 6.87 - 6.93 (m, 1H), 6.73 - 6.84 (m, 2H), 3.69 (s, 3H), 
3.49 (s, 3H); 
13
C NMR (DMSO-d6, 75 MHz) δ 55.2 (CH3), 55.4 (CH3), 110.7 (CH), 112.0 (CH), 
122.1 (CH), 126.7 (CH), 126.8 (C), 127.4 (CH), 127.8 (CH), 129.2 (C), 130.3 (CH), 139.6 (C), 
147.6 (C), 150.4 (C), 167.3 (C). HRMS (ESI) m/z calcd for C21H18NO3
80
Se ([M + H]
+
); 
412.0452. Found 412.0445. 
2-Chloro-10H-phenoselenazin-10-yl(phenyl)methanone (15g): Yellow solid (79%). mp = 
155-158°C. 
1
H NMR (DMSO-d6, 300 MHz) δ 7.68 - 7.78 (m, 3H), 7.13 - 7.37 (m, 9H); HRMS 
(ESI) m/z calcd for C19H13ClNO
80
Se ([M + H]
+
); 385.9851. Found 385.9841. 
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1-(2-Chloro-10H-phenoselenazin-10-yl)-2-phenylethanone (15h): Yellow semi-solid oil 
(73%). 
1
H NMR (DMSO-d6, 300 MHz) δ 7.75 ( br s, 1H), 7.67 (d, J = 8.3 Hz, 3H), 7.42 (t, J = 
7.9 Hz, 2H), 7.23 - 7.37 (m, 2H), 7.12 - 7.23 (m, 4H), 6.95 (m, 2H), 3.74 (s, 2H); HRMS (ESI) 
m/z calcd for C20H15ClNO
80
Se ([M + H]
+
); 400.0007. Found 399.9998. 
1-(2-Chloro-10H-phenoselenazin-10-yl)-3-phenylpropan-1-one (15i): Yellow solid (84%). mp 
= 90-92°C. 
1
H NMR (DMSO-d6, 300 MHz) δ 7.74 (d, J = 8.5 Hz, 3H), 7.10 – 7.45 (m, 9H), 2.69 
- 2.87 (br s, 4H); HRMS (ESI) m/z calcd for C21H17ClNO
80
Se ([M + H]
+
); 414.0164. Found 
414.0155.  
2-Chloro-10H-phenoselenazin-10-yl(4-methoxyphenyl)methanone (15j): White solid (47%). 
mp = 155-156°C. 
1
H NMR (DMSO-d6, 300 MHz) δ 7.64 - 7.78 (m, 3H), 7.31 (d, J = 8.2 Hz, 2H), 
7.16 - 7.26 (m, 4H), 6.80 (d, J = 8.4 Hz, 2H), 3.70 (s, 3H); HRMS (ESI) m/z calcd for 
C20H15ClNO2
80
Se ([M + H]
+
); 415.9957. Found 415.9947. 
2-Chloro-10H-phenoselenazin-10-yl(3-methoxyphenyl)methanone (15k):
 
Yellow solid (52%). 
mp =  135-137°C. 
1
H NMR (DMSO-d6, 300 MHz) δ 7.36 - 7.80 (m, 3H), 7.26 - 7.38 (m, 2H), 
7.11 - 7.25 (m, 3H), 6.90 (d, J = 8.2 Hz, 1H), 6.78 - 6.86 (m, 2H), 3.61 (s, 3H); HRMS (ESI) m/z 
calcd for C20H15ClNO2
80
Se ([M + H]
+
); 415.9957. Found 415.9947. 
2-Chloro-10H-phenothiazin-10-yl(3,4-methoxyphenyl)methanone (15l): Yellow solid (28%). 
mp = 138-140°C. 
1
H NMR (DMSO-d6, 300 MHz) δ 7.65 - 7.78 (m, 3H), 7.26 - 7.35 (m, 2H), 
7.15 - 7.24 (m, 2H), 6.73 - 6.96 (m, 3H), 3.69 (s, 3H), 3.50 (s, 3H); HRMS (ESI) m/z calcd for 
C21H17ClNO3
80
Se ([M + H]
+
); 446.0062. Found 446.0054. 
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7.2 Biochemistry 
7.2.1 Cholinesterase Assay 
The compounds were evaluated in a 96-well plate with reference compounds tacrine, donepezil 
and galantamine. Various concentrations of test compounds (1, 5, 10, 25, 50 μM) were used to 
analyze ChE inhibition. Each well contained a total of 250 μL; 160 μL of DTNB, 50 μL of 
enzyme (AChE or BuChE), 10 μL of test compound and 30 μL of acetyl or butyryl thiocholine 
iodide. Acetyl or butylrylthiocholine iodide solutions were prepared in ultra pure water (UPW, 
15 mM) and were added after a 5 minute incubation. Blank solutions contained 10 μL of DMSO 
and controls contained 8 μL of buffer A and 2 μL of DMSO. To ensure no interference from 
external light sources, the 96-well plate was kept away from light during the incubation period. 
Absorbance values were taken every minute for 5 minutes at 412 nm. To determine the 50% 
inhibitory concentration (IC50), the average absorbance values taken at the six different time 
intervals were subtracted from the average control absorbance. This value was then divided by 
the average control absorbance to give percent inhibition of a given test compound. Finally, by 
plotting the percent inhibition against the test compound concentration logarithmically, the IC50 
was determined. The results were expressed as mean ± standard deviation (SD) of two separate 
experiments (n = 3).  
100% activity absorbance test compound absorbance
100% activity absorbance
 x 100% 
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Preparation of cholinesterase assay solutions: 
Buffer A was prepared by dissolving 3.029 g of Trizma base (Sigma), 2.922 g of NaCl and 
2.033 g of MgCl2•6H2O in 450 mL of UPW. The 1M HCl was added to the solution until pH 8.0, 
and finally the solution was filled up to 500 mL with UPW. 
Buffer B was prepared by dissolving 3.029 g of Trizma base (Sigma) in UPW followed by 0.50 
g of BSA and 20 mL of UPW. Finally, add 0.086 mL of 1M HCl was added until pH was 8.0 
then the volume was adjusted to 50 mL with UPW.   
Human acetylcholinesterase solution (0.22 units/mL) was prepared by dissolving the supplied 
amount of hAChE (425.95 units/mg) in 9.4 mL of buffer B. 0.5 mL of the aforementioned 
solution was added to an additional 0.5 mL of buffer B; 0.011 mL of this solution was added to 
5.31 mL of buffer B yielding a final concentration of 0.22 units/mL. 
Human butyrylcholinesterase solution (0.12 units/mL) was prepared by dissolving the 
supplied amount of hBuChE (221 units/mg) in 9.0 mL of buffer B. 0.5 mL of the aforementioned 
solution was added to an additional 0.5 mL of buffer B; 0.010 mL of this solution was added to 
9.198 mL of buffer B yielding a final concentration of 0.12 units/mL. 
7.2.2 Anti-Amyloid Aggregation Assay 
The compounds were evaluated in a 384-well plate for their ability to inhibit the formation of 
Aβ1-42 aggregates (self-induced). Each well contained: 55 μL of ThT, 10 μL of test compound 
solution, 10 μL of Aβ1-42 and 25 μL of phosphate buffer. Background control solutions contained 
55 μL of ThT and 44 μL of phosphate buffer and 1 μL of DMSO. Compound background 
solutions contain 55 μL of ThT, 35 μL of phosphate buffer and 10 μL of test compound. The 
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Aβ1-42 control solutions contain 55 μL of ThT, 34 μL of phosphate buffer, 1 μL of DMSO and 10 
μL of Aβ1-42. The solutions were then incubated for 16 hr. 55 μL of ThT was then added to all 
wells and measurements are taken at 5 minute intervals for 16 hours at 446 nm (excitation) and 
490 nm (emission). The direct measure of a test sample’s ability to block Aβ fibril aggregation 
was determined by comparing fluorescence intensities in the presence and absence of inhibitors. 
The percentage inhibition was calculated using the equation 100% control value (i.e. no inhibitor) 
- [(IFi - IFo)] where IFi and IFo are the fluorescence intensities in the presence of ThT and 
absence of ThT before 16 h incubation, respectively. The results were expressed as mean ± 
standard deviation (SD) of two separate experiments (n = 3). Reference compound orange G was 
used as the reference agent  for comparison.   
Preparation of anti-amyloid aggregation assay solutions: 
ThT solution was prepared by dissolving 0.94 g of glycine and 1.20 mg of ThT in 150 mL UPW. 
Using a 50 mM aqueous solution of NaOH, the pH of the buffer solution was adjusted to pH 8.5 
and the volume was made up to 250 mL with UPW. 
Sodium phosphate dibasic heptahydrate buffer was prepared by dissolving 28.81 g of 
Na2HPO4·7H2O in 300 mL of UPW. The pH of the buffer solution was adjusted to pH 8.0 and 
the volume was made up to 500 mL with UPW. 
Aβ1-42 peptide solution was made by dissolving 1 mg of peptide hexafluoro-2-propanol (HFIP) 
in 1 mL of 1% ammonium hydroxide.  
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7.2.3 DPPH Antioxidant Assay 
The compounds were evaluated in a 96-well plate with reference compounds trolox. The test 
compounds were prepared in methanol (50 μM). Each well contained: 50 μL of test compound 
and 200 μL of DPPH solution. Blank solutions contained 50 μL of test compound and 200 μL of 
MeOH. Negative control solutions contained 50 μL of MeOH and 200 μL of DPPH. The 96-well 
plate was allowed to incubate at room temperature with shaking in the absence of light for 60 
minutes and absorbance was measured at 517 nm. To determine the percent inhibition, the 
absorbance of the negative control was subtracted by the difference of the test compounds and 
blank. This value was divided by the absorbance of the negative control to obtain percent 
inhibition. The results were expressed as mean ± standard deviation (SD) of two separate 
experiments (n = 3). 
Negative control absorbance (test compound absorbance blank absorbance)
Negative control absorbance
  x 100% 
Preparation of DPPH solution: 
DPPH stock solution was freshly prepared by adding 1.97 mg of DPPH to a 50 mL volumetric 
flask. The solution was made up to 40 mL with anhydrous methanol. 10 mL of this solution was 
dluted with an additional 10 mL of anhydrous methanol.  
7.2.4 MTT Cell Viability Assay 
The cell viability assay was was conducted by Nyasha Gondora from Dr. Beazely’s lab. The SH-
SY5Y neuroblastoma cells were plated at a density of 4 x10
5
 per mL in 96 well plates with 
complete growth media consisting of DMEM and Ham’s F12 in a 1:1 ratio, supplemented with 
2.5 nM glutamate and 10% fetal bovine serum at 37 °C in 5% CO2. The cells were incubated 
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overnight and treated with the test sames at various concentrations (1, 10 and 50 μM) for 24 hrs 
at 37 °C in triplicates (n = 3). The MTT was added in 10% of the culture medium volume to each 
well and the cells were cultured for an additional 3 hrs at 37 °C in 5% CO2. After incubation, the 
resulting formazan crystals were solubilized with MTT reagent solution in each well and the 
absorbance was taken at 570 nm. All results were expressed as a relative percent of MTT to 
untreated controls. 
7.3 Computational Chemistry 
Docking experiments were performed using Discovery Studio Client provided by Structure-
Based-Design from BIOVIA/Accelrys Inc. The X-ray crystal structures for hAChE, hBuChE and 
Amyloid fibril model were obtained from the RCSB Protein Data Bank (PDB ID: 4EY7, 1POI 
and 2LMN). The amyloid peptide consisting of chains A and B was extracted from the PDB file 
for the Aβ1-40 dimer model. The N-terminal octapeptide region (1-8) was not considered for 
modeling since those residues are not involved in amyloid aggregation. The ligand molecules or 
interest were constructed using the “Build Fragment” tool built-in to the Discovery Studio Client. 
All compounds were minimized reaching a convergence of 0.01 kcal/mol Å. Docking 
experiments were carried out by both LibDock (rigid) and CDocker (flexible) commands in the 
receptor-ligand interactions protocol within the Discovery Studio library with a 10 – 15 Å sphere 
radius centered around each active site of each receptor. The Chemistry at HARvard 
Macromolecular Mechanics (CHARMm) force field was applied to all docking protocols.  
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7.4 Appendix A: UV scan of compounds 13 and 15f at 50 µM in methanol 
 
Figure A.1: UV scan of compound 13 at 50 µM in methanol 
 
Figure A.2: UV scan of compound 15f at 50 µM in methanol 
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